EIN Presswire: Breast Cancer Press Releases

Rates of avoidable deaths reduced, yet significant room for improvement remains

Thu, 24 May 2012 15:26:00 +0000

Rates of avoidable deaths reduced, yet significant room for improvement remains

Canada NewsWire

Fewer avoidable deaths suggest timely health care and disease prevention are having an impact

OTTAWA, May 24, 2012 /CNW/ - The rate of deaths that could potentially be avoided through timely and effective health care and disease prevention dropped from 373 per 100,000 Canadians in 1979 to 185 per 100,000 Canadians in 2008. Health Indicators 2012, the most recent edition of the report produced annually by the Canadian Institute for Health Information (CIHI) and Statistics Canada, includes updates on more than 40 measures for Canadian regions, including a suite of new avoidable mortality indicators.

"When we look into pan-Canadian results for avoidable deaths," says Jeremy Veillard, Vice President, Research and Analysis, CIHI, "we can determine the respective impact of prevention efforts and of health care improvements."

The report reveals that the rate of deaths that could be avoided by preventing disease from developing or an injury from occurring has decreased by 47% over a 30-year period. The rate for Canadians went from 225 per 100,000 in 1979 to 119 per 100,000 in 2008.

Meanwhile, deaths that could have been avoided through timely and effective health care intervention were reduced by 56%. This rate went from 149 per 100,000 Canadians in 1979 to 66 per 100,000 in 2008.

The drop in avoidable deaths between 1979 and 2008 was mainly due to reductions in deaths related to circulatory diseases such as heart disease, which decreased by 72%. If death rates for these illnesses had remained unchanged for the 30-year period, the overall reduction in avoidable deaths would have been only 19%, based on gains related to other conditions, and not the observed 50%.

"Declines in some areas of avoidable mortality, such as circulatory diseases, demonstrate that great results can be achieved through collaboration across the health care system and other sectors," says Veillard. "But, there is still work to be done."

Provincial and territorial variations were observed for both the rates and trends over time. While rates of avoidable deaths have declined in almost all jurisdictions, some experienced greater reductions than others. Moreover, provinces with lower avoidable death rates in 1979 were among those with the highest rates 30 years later. A relatively smaller reduction in deaths due to injuries was one of the key drivers of this finding.

According to Health Indicators 2012, Canada's rates of avoidable mortality are the third lowest (behind Japan and France) of the G7 countries. Learning from the best, nationally and internationally, may provide insights on the successful strategies for reducing untimely deaths and help to identify areas for more detailed investigation.

Avoidable death rates vary greatly based on sex and income

Between 1979 and 2008, rates of avoidable mortality among men dropped by more than half (55%), compared with a 43% reduction among women. Men have higher rates of avoidable deaths than women, even after substantial reductions over the past 30 years. Circulatory diseases continue to be the number one cause of avoidable deaths among men, whereas cancers (such as lung and breast cancer) are the main cause of avoidable deaths among women.

Rates of avoidable deaths varied significantly by socio-economic group (as measured by neighbourhood income quintile). For example, people living in the least affluent neighbourhoods were twice as likely to die from preventable causes as those in the most affluent neighbourhoods.

About Health Indicators

CIHI's Health Indicators annual report, produced in partnership with Statistics Canada, presents more than 40 comparable measures of health and health system performance by health region, province and territory. For the first time, this year's report features a section on avoidable mortality that serves to focus attention on the influence of the health system on population health. In addition, the report introduces a suite of new acute-care readmission indicators, which will facilitate comprehensive evaluation of readmissions for all patient groups.

The report and the following figures and table are available from CIHI's website, at www.cihi.ca.

Figure 1: Avoidable Mortality Indicators (see page 5 in the report)

Figure 2: Potentially Avoidable Mortality, by Cause of Death, Canada, 1979 and 2008 (Figure 5 in the report)

Figure 3: Mortality From Preventable and Treatable Causes, by Sex, Canada, 1979 to 2008 (Figure 12 in the report)

SOURCE CANADIAN INSTITUTE FOR HEALTH INFORMATION

UL And Value Capture Team Up To Support Healthcare Leaders Seeking Lean Transformation

Thu, 24 May 2012 13:45:00 +0000

UL And Value Capture Team Up To Support Healthcare Leaders Seeking Lean Transformation

New Offerings Advise on Principles and Processes to Help Reduce Medical Errors, Avoid Malpractice Litigation and Mitigate Rising Costs

PR Newswire

JACKSONVILLE, Fla., May 24, 2012 /PRNewswire/ -- Today UL, a world leader in advancing safety, goes to market with new healthcare advisory services in collaboration with Value Capture LLC. The services aim to guide healthcare executives seeking to transform the performance of their organizations with a unifying focus on safety and quality.

With Value Capture, an organization featuring 15 years of proven results in healthcare advisory, UL enhances its ability to deliver a unique set of services that combine its century-long safety mission with its expertise in Lean. The offerings are available immediately from Knowledge Services, UL's fast-growing training, advisory and software solutions business unit, and can be supplied to customers anywhere in the world.

A frequently-cited report from the Institute of Medicine estimates that in the U.S. alone, between 44,000 and 98,000 people die annually from medical mistakes. And current estimates from the Agency for Healthcare Research and Quality place medical errors as the eighth leading cause of death, making medicine deadlier than highway accidents, breast cancer, or AIDS.

The combination of medical errors, malpractice litigation and ballooning costs are forcing the industry to increasingly search for innovative ways to serve patients, manage their organizations and engage staff. UL and Value Capture have proven that the application of Lean principles and methodology in a quest for measurable excellence can be part of the solution that the healthcare industry so desperately needs.

The collaboration offers comprehensive solutions designed to help achieve the highest levels of quality and safety, lowest cost, and shortest customer response time, without tradeoffs. It provides access to advisory and training services that give guidance on a true Lean transformation at all levels and beyond just one department. The resulting shift can challenge the traditional paradigms of the leadership top-down management approach and create an environment that engages all employees in the improvement process.

"Leaders of hospitals, ambulatory care centers and other healthcare organizations using our advisory services develop a comprehensive understanding of the field's most powerful leadership model, anchored by lean principles, and leverage it to produce remarkable, sustainable results," said Juan Amador, director of the Center for Continuous Improvement & Innovation for UL Knowledge Services. "The advisory model from Value Capture has consistently given institutions the skills to produce 50 to 90 percent reductions in harm to workers and patients while stripping millions in waste from the system and speeding up the ability to meet patient needs."

By empowering individuals and organizations in this industry, giving them the leadership framework, expertise and techniques required, they can conduct their own Lean transformation.

"Working with UL pairs Value Capture with another of the world's leading organizations on the quest for perfect safety, across everything an organization does," said Geoff Webster, Value Capture managing director. "It extends our reach to CEOs who share our mission to create healthcare organizations demonstrating levels of excellence in safety, quality and profitability that set a new standard for the industry."

An up-to-date listing of advisory and training offerings from UL and Value Capture is available online at www.ulknowledgeservices.com or www.valuecapturellc.com.

About UL

UL is a premier global safety science company with more than 100 years of proven history. Employing nearly 9,000 professionals in 46 countries, UL is evolving the future of safety with five distinct business units – Product Safety, Environment, Life & Health, Verification and Knowledge Services – to meet the expanding needs of customers and the global public. For more information on UL's family of companies and network of 95 laboratory, testing and certification facilities, go to UL.com.

About Value Capture

Over the past 15 years, Value Capture has been associated with some of the earliest and most compelling demonstrations that perfect safety and clinical performance, with enhanced financial outcomes, are achievable in healthcare. The organization has done so by helping healthcare leaders drive one unified organizational strategy, not separate from the business case, but as THE business case for the organization. It is based on the principles of so-called deep Lean, but goes far beyond to encompass every element of a true leadership system, from organized and cascaded strategic planning to standard work that flows from leaders to the front lines and back again.

Media Contact
Natasha LaBruce
+1.919.316.5292
natasha.labruce@ul.com

SOURCE UL

Merz Aesthetics Unveils Grand Prize Winner of the Stand and Deliver Program

Thu, 24 May 2012 12:01:00 +0000

Merz Aesthetics Unveils Grand Prize Winner of the Stand and Deliver Program

America Chooses Michelle Rubin to Receive $10,000 to Help Support Her Non-Profit Autism After 21

PR Newswire

SAN MATEO, Calif., May 24, 2012 /PRNewswire/ -- Today, Merz Aesthetics, Inc., the exclusive distributor of Asclera® (polidocanol) Injection in the U.S., announces Michelle Rubin as the grand prize winner of the "STAND AND DELIVER" program, an initiative created to honor women who take a stand and make a difference in their communities. Michelle Rubin, founder and director of Autism After 21, a nonprofit 501(c) organization which provides opportunities and services for autistic adults over the age of 21 in Boca Raton, Fla., will receive a donation of $10,000 to her organization and her choice of beauty treatments by a top dermatologist in her local community.

Michelle, who was chosen by a nationwide vote via the campaign's website www.Asclera.com/standanddeliver, is a woman who proved that she stands and delivers for her cause. With more than two decades of service to the autistic community and a mother of a 22-year old autistic son, Michelle identified the need for programs to help autistic adults over the age of 21. Michelle was nominated by Molly Murphy, one of the committee members of Autism After 21, noting that "Michelle is an inspiration to parents, community leaders and others through her comprehensive understanding of the needs of the autistic community and her determination to meet those needs one individual at a time."

"I am amazed by the outpouring of support and honored to have been chosen as this year's winner of the STAND AND DELIVER program which was sponsored by Merz Aesthetics," says Michelle Rubin. "This is a once in a lifetime experience and I'm honored to have the chance to donate $10,000 to Autism After 21 in hopes that we will be able to provide young adults with autism the life skills and training they need to independently live full and functioning lives within our community."

Merz Aesthetics, the exclusive distributor of Asclera® (polidocaol) in partnership with an advisory panel of Rhonda Smith, Founder of Breast Cancer Partner; Linda Meacham, Volunteer at Fisherman's Mark; Janey Russell, Founder of SHINE ON Tucson, who were selected for their abilities to stand and deliver, conducted a nationwide search for women who are changing their communities through support of a 501(c)(3) non-profit organization.

Following a nomination period, the advisory panel selected three finalists that are committed to their communities and work hard to make an impact. The three finalists' stories were featured on the contest website and from February 20 through April 15, 2012, the public had the opportunity to vote for the woman they felt best deserved the grand prize. To learn more about the advisory panel and the three finalists, visit the campaign's website at www.Asclera.com/standanddeliver.

"On behalf of Merz Aesthetics and the Asclera brand, I commend Michelle Rubin for her hard work and commitment to her organization, Autism After 21," said Pat Altavilla, Vice President, Global Marketing at Merz Aesthetics, Inc. "Merz Aesthetics is pleased to be able to present her with a $10,000 donation to her organization and a consultation with a top dermatologist of her choice. Michelle is an example to us all and a dedicated woman that defines exactly what it means to make a real difference in people's lives. We look forward to working with Michelle to support the STAND AND DELIVER initiative next year and continue to celebrate inspirational women across the U.S."

To learn more about Michelle's story and the two other finalists, Sara Finger, executive director of Wisconsin's Alliance for Women's Health and Carol Burnett, community outreach and recruitment coordinator of Long Island Head Start, visit the "Meet the Finalists" section on the program's website at http://www.asclera.com/standanddeliver/finalists.cfm.

About Asclera®

The FDA approved Asclera® (polidocanol) Injection on March 30, 2010 to sclerose uncomplicated spider veins (varicose veins less than or equal to 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity, making it the first sclerosant to be approved by FDA in over 60 years.

About Merz Aesthetics

Merz Aesthetics, Inc. is part of the Merz Pharma Group. Merz Aesthetics, with headquarters in San Mateo, California, partners with Merz Aesthetics business units in 16 countries and cooperates with more than 30 distributors worldwide.

Founded in 1908 by Friedrich Merz, Merz introduced the world's first anti-wrinkle treatment in 1953 after conducting extensive research on the effects of revitalizing skin care essences. As part of the Merz Pharma Group of companies, Merz Aesthetics leverages more than a century of Merz's healthcare expertise with its products and unparalleled service to the field of aesthetic dermatology. The Merz legacy continues today with Merz Aesthetics' innovative portfolio of products.

Indication:

Asclera® (polidocanol) Injection is a prescription medicine that is used in a procedure called sclerotherapy to remove unwanted veins on your legs. It is administered by a healthcare provider to treat two types of veins:

Uncomplicated spider veins (very small varicose veins </= 1 mm in diameter)
Uncomplicated small varicose veins (1 to 3 mm in diameter) known as reticular veins

Asclera® has not been studied in varicose veins more than 3 mm in diameter.

IMPORTANT SAFETY INFORMATION:

For intravenous use only.

CONTRAINDICATIONS: Asclera® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute vein and blood clotting diseases.

WARNINGS AND PRECAUTIONS:

Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized. Please notify your healthcare provider if you have a known history of severe allergies or allergy to polidocanol.

Accidental injection into an artery can cause severe necrosis, ischemia or gangrene. If this occurs, consult your healthcare provider or a vascular surgeon immediately.

Unintentional injection of Asclera outside of the vein can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected by your healthcare provider.

Severe adverse local effects, including tissue necrosis, may occur following flow of the product outside of the vein; therefore, the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and walk for 15- 20 minutes. Your healthcare provider will provide monitoring during this period to treat any possible anaphylactic or allergic reactions.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins, or as directed by your Healthcare Provider. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera® and were more common with Asclera® than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting.

You are encouraged to report any suspected adverse events. To report SUSPECTED ADVERSE REACTIONS, contact your Healthcare Provider, Merz Aesthetics at 1-866-862-1211, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please talk to your healthcare provider should you have any questions about Asclera®

SOURCE Merz Aesthetics

When One Plus One Equals Three

Thu, 24 May 2012 09:00:00 +0000

When One Plus One Equals Three

PR Newswire

SANTA ROSA, Calif., May 24, 2012 /PRNewswire/ -- In a groundbreaking study, Modified Citrus Pectin (MCP), a highly researched natural compound enhanced the anti-cancer effects of two poly-botanical formulas. When co-administered with formulas that attack breast and prostate cancer, MCP significantly increased their anti-cancer action, further reducing metastasis in highly invasive breast and prostate cancer cells. The study was led by researchers at the Cancer Research Laboratory at Indiana University Health and Indiana University School of Medicine, and published in the peer review journal Integrative Cancer Therapies.

"We asked a simple question of whether one plus one can equal more than two," said lead investigator Dr. Daniel Sliva, associate professor at the Indiana University School of Medicine. "We know that certain molecules in cancer cells are responsible for their aggressive behavior.
The synergistic effects seen in this study show that we can further suppress these molecules and significantly reduce the cancer cells' aggressiveness."

In the study, low concentrations of the anti-breast cancer formula decreased breast cancer cell adhesion to human fibronectin by 21 percent. However, when co-administered with Modified Citrus Pectin, researchers observed a 40 percent decrease.

In addition, the anti-prostate cancer formula, administered alone, decreased prostate cancer cell adhesion by 9 percent. When MCP was added, adhesion was suppressed by up to 40 percent.

The study also showed that cancer cell migration was also reduced by combining MCP with the prostate and breast formulas.

"This new study is particularly important because it demonstrates that when MCP is combined with either the prostate or breast formula, lower dosages provided more powerful synergistic anti-cancer effects than were observed when these supplements were studied on their own," said
co-author and formulator, Dr. Isaac Eliaz.

It is especially important because of the recent poster presentation of the breast formula at AACR (American Association for Cancer Research), demonstrating its dramatic ability to decrease breast to lung metastasis in an orthotopic triple negative breast cancer animal model.

In addition to examining the aggressive behavior of breast and prostate cancer cells, researchers also assessed levels of urokinase plasminogen activator (uPA), a protein secreted by cancer cells. High levels of uPA promote cell adhesion, migration and invasion, contributing to cancer
metastasis. As a result, uPA is used as a bio-marker for invasive cancer cells. Previous studies had shown that the poly-botanicals alone suppressed uPA expression. The current study shows that uPA secretion and cancer cell migration were further restricted when cancer cells were
treated with the breast or prostate formulas combined with MCP.

For more information on the following:
*           Breast Health Formula www.BreastHealthSolutions.org
*           Prostate Health Formula www.ProstateHealthSolutions.org
*           Modified Citrus Pectin www.MCPRecommends.org
*           Published Study http://tinyurl.com/cpukkhq

Source: Jiang J, Eliaz I, Sliva D. Synergistic and Additive Effects of Modified Citrus Pectin With Two Polybotanical Compounds, in the Suppression of Invasive Behavior of Human Breast and Prostate Cancer Cells. Integr Cancer Ther. 2012 Apr 24. doi: 10.1177/1534735412442369

About Better Health Publishing

Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

SOURCE Better Health Publishing

MinuteClinic Signs Clinical Collaboration with Atlantic Health System for Clinic Locations in Five-County Region of Northern and Central New Jersey

Wed, 23 May 2012 12:00:00 +0000

MinuteClinic Signs Clinical Collaboration with Atlantic Health System for Clinic Locations in Five-County Region of Northern and Central New Jersey

Electronic Medical Record Integration Included In Agreement to Improve Care Coordination

PR Newswire

WOONSOCKET, R.I. and MORRISTOWN, N.J., May 23, 2012 /PRNewswire/ -- MinuteClinic, the retail health care division of CVS Caremark (NYSE: CVS) and Atlantic Health System, one of the largest non-profit health care systems in New Jersey comprised of Morristown Medical Center, Goryeb Children's Hospital, Overlook Medical Center in Summit, N.J. and Newton Medical Center have entered into a clinical affiliation to enhance access to high quality, affordable health care services in Northern and Central New Jersey.

The agreement includes nine MinuteClinic walk-in medical clinics open seven days a week inside select CVS/pharmacy stores in Morris, Somerset, Sussex and Union counties and parts of Essex county. The clinics are staffed by nurse practitioners who provide treatment for common family illnesses and administer wellness and prevention services, including health condition monitoring.

Under the agreement, Atlantic Health System physicians will serve as medical directors for MinuteClinic locations in Northern and Central New Jersey. In addition, MinuteClinic and Atlantic Health System will collaborate on patient education and disease management initiatives and will inform patients of the services each offers. Atlantic Health System will accept patients who need a level of care that is not provided at MinuteClinic. Signage at MinuteClinic locations will inform patients that each site has a clinical affiliation with Atlantic Health System.

"Our affiliation with Atlantic Health System will help MinuteClinic make the best use of our clinics in Northern and Central New Jersey to offer better access to high quality health care services and to lower costs for patients and employers," said Andrew Sussman, M.D., President, MinuteClinic and Senior Vice President/Associate Chief Medical Officer, CVS Caremark. "We look forward to having Atlantic Health System's physicians collaborate with our practitioners to provide quality oversight, teaching and back-up so we can provide the best care at the lowest overall cost."

MinuteClinic and Atlantic Health System will begin to work toward fully integrating electronic medical record systems to streamline communication around all aspects of each individual's care. With patient permission, MinuteClinic will electronically share medical histories and visit summaries with other Atlantic Health System locations in Northern and Central New Jersey. In the meantime, MinuteClinic will continue its standard practice of sending patient visit summaries to primary care providers via fax or mail, typically within 24 hours.

"Atlantic Health System is committed to improving the health of our communities," said Joseph Trunfio, President and CEO of Atlantic Health System. "By providing access to our physicians' expertise through MinuteClinic services, we can help members of the community to lead healthier lives, in a new, innovative way."

MinuteClinic practitioners specialize in family health care and can diagnose, treat and write prescriptions for common illnesses such as strep throat and ear, eye, sinus, bladder and bronchial infections. Minor wounds, abrasions, skin conditions and joint sprains are treated, and common vaccinations such as influenza, tetanus, pneumonia, pertussis and Hepatitis A & B are available at most locations. Walk-in camp, sports and college physicals for adolescents are available daily. In addition, MinuteClinic administers a series of wellness services designed to help consumers identify lifestyle changes needed to improve their current and future health, including screenings and monitoring for diabetes, high blood pressure and high cholesterol.

No appointments are required at MinuteClinic and most health insurance is accepted. Clinics in New Jersey are open Monday – Friday, 8:30 a.m. to 7:30 p.m.; Saturday, 9 a.m. to 5:30 p.m. and Sunday, 9 a.m. to 4:30 p.m.

About Atlantic Health System
Atlantic Health System is one of the largest non-profit health care systems in New Jersey, comprised of Morristown Medical Center, Goryeb Children's Hospital, Overlook Medical Center in Summit and Newtown Medical Center. The four medical facilities have a combined total of 1,310 licensed beds and more than 2,852 affiliated physicians providing a wide array of health care services to the residents of Northern and Central New Jersey. The medical centers, and Goryeb as part of MMC, are accredited by The Joint Commission. Specialty service areas include advanced cardiovascular care, pediatric medical and surgical specialties, neurology, orthopedics and sports medicine. Each of these programs has earned top ratings and recognitions in their respective fields. Atlantic Health System is the official health care partner of the New York Jets and an official health care provider of the New Jersey Devils.

Atlantic Health System has been chosen for the past four consecutive years by FORTUNE® as one of the magazine's "100 Best Companies to Work For®." The organization has also been recognized five times by AARP as one of the "Best Employers for Workers over 50." Inside Jersey magazine partnered with Castle Connolly Medical Ltd. and ranked Morristown Medical Center the top hospital in New Jersey for the second consecutive year, while also naming it the No. 1 hospital for coronary surgery, treatment of heart failure, hip and knee repair, and pediatric cancers. Overlook Medical Center was rated the No. 1 hospital in NJ for the treatment of neurological diseases for the third consecutive year, and for the second year as No. 1 for treating strokes. It was also ranked among the top three hospitals across several categories, including overall quality, high-risk pregnancies, hip and knee repair, and prostate and breast cancer treatment. Newton Medical Center was voted the state's No. 1 hospital with 350 beds or fewer, and also ranked first in this category for the treatment of pediatric, prostate and breast cancers.

Atlantic Health System is a Major Clinical Research Affiliate with The Cancer Institute of New Jersey and is the primary academic and clinical affiliate in New Jersey of Mount Sinai School of Medicine and The Mount Sinai Hospital.

About MinuteClinic
MinuteClinic is a division of CVS Caremark Corporation (NYSE: CVS), the largest pharmacy health care provider in the United States. MinuteClinic launched the first retail medical clinics in the United States in 2000 and is the largest provider of retail clinics with more than 600 locations in 25 states and the District of Columbia. By creating a health care delivery model that responds to consumer demand, MinuteClinic makes access to high-quality medical treatment easier for more Americans. Nationally, the company has generated more than 12 million patient visits, with a 95% customer satisfaction rating. MinuteClinic is the first retail health care provider to receive accreditation (2006) and reaccreditation (2009) from The Joint Commission, the national evaluation and certifying agency for nearly 15,000 health care organizations and programs in the United States. For more information, visit www.MinuteClinic.com.

SOURCE MinuteClinic

Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening

Wed, 23 May 2012 11:30:00 +0000

Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening

— A Low-cost, Pain-free, and Non-invasive System Designed for Clinical Use in Developing Countries —

PR Newswire

SAN DIEGO, May 23, 2012 /PRNewswire/ -- Medical Tactile, Inc. (MTI), with the support of The Pre-Mammogram Foundation and Qualcomm Incorporated, today announced that they have developed a pre-commercial SureTouch™Wireless system that uses 3G-enabled tactile sensor technology for breast cancer screening.

According to a publication funded by the Susan G. Komen Foundation, 1.6 million women worldwide were diagnosed with breast cancer in 2010 and 425,000 women died from the disease. Although early detection is the best means to a good prognosis for breast cancer, developing countries are particularly affected because 80 percent of women 30-70 years old live in these regions of the world, while only 10 percent of mammogram procedures are conducted there.

The National Breast Cancer Foundation estimates that approximately 70 percent of newly diagnosed breast cancers are found by women through their sense of touch during regular self-exams. Unfortunately, the average-size lump found through self-exam is approximately 2.5cm, while the average-size lump found by trained clinicians using palpation is approximately 1cm.

The SureTouch system can detect masses as small as 0.5cm by using tactile sensor technology, also known as stress elastography, to measure the reactive pressures generated by cancerous tissue, which can be more than 100 times harder than normal tissue. The current SureTouch system has been cleared by the U.S. Food and Drug Administration for documenting the Clinical Breast Exam (CBE) in the United States and is already used in China, India, Turkey and sixteen other countries as a screening tool for breast cancer. The SureTouch Wireless system can be used effectively to diagnose women of all ages and is designed primarily for use in medical centers by low-skill technicians to provide affordable, radiation-free, comfortable and clinically effective breast exams. 3G wireless connectivity also enables remote evaluation by medical specialists as well as more efficient technical support.

"The Pre-Mammogram Foundation is proud to make SureTouch more accessible to women everywhere," said Eli Yered, Chief Financial Officer of the Pre-Mammogram Foundation. "The many benefits of the current SureTouch system will be amplified by enabling connectivity via 3G wireless technology."

The SureTouch Wireless system is a small, easy-to-use device that consists of a 3G-enabled sensor, touchscreen display, and the SureTouch network. During a breast exam, the clinician uses the sensor to scan the breast and collect images of the tissue. A Bluetooth wireless module provides two-way communication between the sensor and display, allowing the display to provide real-time feedback to help the clinician collect proper data. When the clinician is finished performing the SureTouch Wireless CBE exam, the patient information and exam data are automatically uploaded to the SureTouch Network. Centralized servers on the network receive and process the data, which clinicians can then access using a web browser. Clinicians also have the ability to replay previous exams, compare images from multiple exams and print summary reports.

MTI developed the sensor technology and the application software, The Pre-Mammogram Foundation provided project management and clinical assessment and Qualcomm supported the effort with an initial grant, project management and engineering support in the form of industrial, mechanical and hardware design. Qualcomm also provided software development and integration support to facilitate sending exams via the 3G network.

"SureTouch has the potential to change the way the world detects breast cancer," said MTI Founder and Chief Executive Officer Jae Son, Ph.D. "With the development of SureTouch Wireless, we can now bring the benefits of early detection to countless numbers of women all over the world, of all socioeconomic backgrounds, who would otherwise not have access."

About the Pre-Mammogram Foundation
The Pre-Mammogram Foundation was formed for charitable, scientific, and educational purposes. Its mission is to save lives by promoting research and education on the importance of the sense of touch in the fight against breast cancer. To achieve this mission, the Pre-Mammogram Foundation supports community breast cancer outreach programs, supports clinical breast cancer research and educates women about the importance of touch in the early detection of breast cancer. For more information, please visit www.premammogram.org

About Medical Tactile, Inc. (MTI)
MTI is a privately-held medical device company founded to develop, manufacture and market advanced tactile imaging systems for the early detection of breast cancer. The company's proprietary technology, SureTouch, is designed to assist health care providers who perform manual palpation clinical breast exams. While such exams are the most accessible first-line of defense against breast cancer for most women, they are typically recorded in a relatively primitive format based on hand-drawn figures and verbal descriptions of findings. MTI brings manual palpation exams into the modern era with the company's first-of-its-kind tactile sensing device. SureTouch is an FDA 510k cleared medical device that is able to detect and record abnormalities in a breast at an early stage in a quick, safe and non‐invasive manner. SureTouch is a significant enhancement to the CBE procedure, helping to ensure that women live healthier and happier lives. For more information, visit the MTI website at www.medicaltactile.com

Jae Son, CEO
310-493-9240
Email: jaeson@medicaltactile.com

Eli Yered, CFO of Pre-Mammogram Foundation
323-325-4757
Email: eli.yered@premammogram.org

SOURCE Medical Tactile, Inc.

Antibody Drugs: Technologies and Global Markets

Wed, 23 May 2012 11:04:07 +0000

Antibody Drugs: Technologies and Global Markets

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0801344/Antibody-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide a range of information—from detailed analysis through industry trends—to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies.

The report develops forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target (epidermal growth factor receptor [EGFR], cluster of differentiation [CD] 20, tumor necrosis factor [TNF] alpha, etc.), and by major disease applications from 2011 through 2016. Additionally, we examine strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector.

Our main objective is to present a comprehensive analysis of the current market for therapeutic mAb disease-modifying products and to forecast this market's future direction through 2016.

REASONS FOR DOING THE STUDY

Therapeutic mAbs represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.

During our forecast period from 2011 through 2016, eight new mAbs are forecast to enter the market, and sales of therapeutic mAbs are estimated to grow from approximately $43 billion in 2010 to nearly $58 billion in 2016. Sales of humanized and fully human antibodies for autoimmune/inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and multiple sclerosis are forecast to experience the fastest sales growth.

This period of dynamic growth for humanized and fully human antibodies plus the continued rollout of antibody-drug conjugates (ADCs), also called immunoconjugates, is expected to result in stagnating sales of chimeric antibodies from 2011 through 2016.

INTENDED AUDIENCE

This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.

Both individuals looking for a comprehensive listing of mAbs in human clinical-stage development and individuals looking at how the mAb drug marketplace is expected to change (in terms of sales and technology) in the coming years will find this report extremely useful.

SCOPE OF REPORT

This report analyzes and assesses therapeutic applications of mAbs in human medicine. Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.

Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use. Also excluded are research applications of mAbs.

The scope of the study is global. The "Overview" section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.

The "Technology and Technical Issues" section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The "Products" section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The "Applications" section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn's disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The "Industry Structure" section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The "Company Profiles" section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

INFORMATION SOURCES

The information in this report was derived from the review of more than 200 biotechnology and pharmaceutical companies developing mAbs and the review of journal articles related to mAb therapeutics. Sources of information include PubMed, ClinicalTrials.gov, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA), and company presentations and annual reports.

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES . 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

INFORMATION SOURCES . 3

ANALYST CREDENTIALS 3

RELATED REPORTS . 3

BCC ON-LINE SERVICES . 4

DISCLAIMER . 4

CHAPTER TWO: SUMMARY 5

SUMMARY TABLE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016 ($ MILLIONS) . 6

CHAPTER THREE: OVERVIEW 7

DEFINITIONS 7

DEFINITIONS (CONTINUED) . 8

THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS . 9

THE IMPORTANCE OF ANTIBODY … (CONTINUED) 10

INTELLECTUAL PROPERTY ISSUES AND PATENT LICENSING 11

THE HISTORY OF THE COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

TABLE 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS 12

WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS COMPARED WITH POLYCLONAL ANTIBODY PRODUCTS? 13

VALUATION OF ANTIBODY PRODUCT SALES . 14

CHAPTER FOUR: TECHNOLOGY AND TECHNICAL ISSUES . 15

OVERVIEW . 15

OVERVIEW (CONTINUED) . 16

TABLE 2 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE DRUGS . 17

TABLE 2 (CONTINUED) . 18

TABLE 3 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL ANTIBODIES . 18

THE HAMA PROBLEM AND ITS RESOLUTION . 19

PHAGE DISPLAY AND POLYSOME DISPLAY 20

PHAGE DISPLAY AND POLYSOME … (CONTINUED) 21

DIRECTED EVOLUTION 22

ANTIBODY CLASSES 22

TABLE 4 ANTIBODY TYPES AND DESCRIPTIONS . 23

ANTIBODY FORMS IN PRODUCTS 23

TABLE 5 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 ($ MILLIONS) . 24

TABLE 6 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY

ANTIBODY FORM (NUMBER/%) 25

TABLE 7 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT 25

TABLE 8 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET . 26

ABTIDES 26

ANTIBODY-DRUG CONJUGATES / IMMUNOCONJUGATES 26

ANTISERUMS . 27

BISPECIFIC ANTIBODIES 28

CAMOUFLAGED ANTIBODIES 28

CHIMERIC ANTIBODIES 29

HUMANIZED ANTIBODIES 29

Humanized Antibodies (Continued) . 30

FULLY HUMAN ANTIBODIES 31

PROGENITOR STEM CELLS . 32

SINGLE-CHAIN ANTIBODIES 32

SYNTHETIC ANTIBODIES 33

SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET 34

TABLE 9 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES 34

TABLE 9 (CONTINUED) . 35

TABLE 9 (CONTINUED) . 36

THE SPECIAL CASE OF ENBREL. 36

ANTIBODY TECHNOLOGIES IN DEVELOPMENT 37

AFFIBODIES . 37

DOMAIN ANTIBODIES 37

NANOBODIES . 38

TABLE 10 MONOCLONAL ANTIBODIES IN PHASE 3 DEVELOPMENT 39

TABLE 10 (CONTINUED) . 40

TABLE 11 MONOCLONAL ANTIBODIES IN PHASE 2 DEVELOPMENT 40

TABLE 11 (CONTINUED) . 41

TABLE 11 (CONTINUED) . 42

TABLE 11 (CONTINUED) . 43

TABLE 11 (CONTINUED) . 44

TABLE 11 (CONTINUED) . 45

TABLE 11 (CONTINUED) . 46

TABLE 11 (CONTINUED) 47

TABLE 12 MONOCLONAL ANTIBODIES IN PHASE 1 DEVELOPMENT 47

TABLE 12 (CONTINUED) 48

TABLE 12 (CONTINUED) . 49

TABLE 12 (CONTINUED) . 50

TABLE 12 (CONTINUED) . 51

TABLE 12 (CONTINUED) . 52

NEW DIRECTIONS IN ANTIBODY RESEARCH 53

THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS 53

THE MARKET OPPORTUNITY FOR …(CONTINUED) 54

THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS . 55

THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS 56

THE TRANSGENIC ADVANTAGE . 56

TRADITIONAL PRODUCTION METHODS 57

MICROBIAL FERMENTATION . 58

MAMMALIAN CELL CULTURE 58

THE ENBREL SHORTAGE . 59

THE CRUNCH IN CAPACITY. 59

REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION 60

GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS 61

PRODUCTION OF ANTIBODIES IN ANIMALS . 62

PRODUCTION OF ANTIBODIES … (CONTINUED) . 63

GOATS AS MONOCLONAL ANTIBODIES FACTORIES 64

PRODUCTION OF ANTIBODIES IN PLANTS 64

PLASTIDS 64

TARGETING AND COMPARTMENTALIZING 65

TRANSGENIC SEEDS FOR ANTIBODY STORAGE 65

CHAPTER FIVE: PRODUCTS 66

OVERVIEW . 66

MARKETED PRODUCTS 66

TABLE 13 GLOBAL SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 67

TABLE 14 U.S. SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 68

TABLE 15 REST OF WORLD SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 ($ MILLIONS) . 69

GEMTUZUMAB OZOGAMICIN (MYLOTARG) 70

DACLIZUMAB (ZENAPAX) 71

Daclizumab (Zenapax) (Continued) 72

TABLE 16 DACLIZUMAB CHOICE STUDY RESULTS . 73

CATUMAXOMAB (REMOVAB) 74

TOCILIZUMAB (ACTEMRA, ROACTEMRA, RG1569) . 75

TRASTUZUMAB (HERCEPTIN, RG597) . 76

Trastuzumab (Herceptin, RG597) (Continued) 77

BEVACLIZUMAB (AVASTIN, RG435) . 78

Bevaclizumab (Avastin, RG435) (Continued) 79

Bevaclizumab (Avastin, RG435) (Continued) 80

CETUXIMAB (ERBITUX) . 81

Cetuximab (Erbitux) (Continued) . 82

PANITUMUMAB (VECTIBIX) 83

Panitumumab (Vectibix) (Continued) . 84

IBRITUMOMAB TIUXETAN (ZEVALIN) 85

Results of Trials . 86

Sales of Zevalin 87

ALEMTUZUMAB (LEMTRADA, CAMPATH, MABCAMPATH) 88

Alemtuzumab (… (Continued) 89

Alemtuzumab (… (Continued) 90

NATALIZUMAB (TYSABRI) . 91

TABLE 17 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS 92

Natalizumab (Tysabri) (Continued) 93

TOSITUMOMAB-I (BEXXAR) 94

Tositumomab-I (Bexxar) (Continued) . 95

OFATUMUMAB (ARZERRA) 96

Ofatumumab (Arzerra) (Continued) . 97

RITUXIMAB (RITUXAN, MABTHERA, RG105) . 98

INFLIXIMAB (REMICADE) 99

Infliximab (Remicade) (Continued) . 100

DENOSUMAB (PROLIA, XGEVA) . 101

IPILIMUMAB (YERVOY, MDX-010) 102

ADALIMUMAB (HUMIRA) . 103

GOLIMUMAB (SIMPONI) 104

CANAKINUMAB (ILARIS, ACZ885) 105

ECULIZUMAB (SOLIRIS) . 106

PALIVIZUMAB (SYNAGIS) 107

ABCIXIMAB (REOPRO) 108

Abciximab (ReoPro) (Continued) . 109

Abciximab (ReoPro) (Continued) . 110

RANIBIZUMAB (LUCENTIS) . 111

Ranibizumab (Lucentis) (Continued) 112

MUROMONAB (ORTHOCLONE OKT3) 113

OMALIZUMAB (XOLAIR) . 113

USTEKINUMAB (STELARA, CNTO 1275) 114

Ustekinumab (Stelara, CNTO 1275) (Continued) 115

CERTOLIZUMAB PEGOL (CIMZIA) . 116

BASILIXIMAB (SIMULECT) 116

Basiliximab (Simulect) (Continued) 117

BELIMUMAB (BENLYSTA) . 118

NIMOTUZUMAB . 119

PRODUCTS IN DEVELOPMENT . 119

TANEZUMAB (RN624) 119

VEDOLIZUMAB (MLN0002). 120

LY2127399 121

OTELIXIZUMAB . 121

MEPOLIZUMAB (BOSATRIA) 122

TEPLIZUMAB (MGA031, HOKT3-GAMMA1) . 122

BAPINEUZUMAB (AAB-001) . 123

GANITUMAB (AMG 479) 124

OBINUTUZUMAB (AFUTUZUMAB, GA101, RG7159) 125

ZANOLIMUMAB (FORMERLY HUMAX-CD4) . 126

RESLIZUMAB (CINQUIL) 127

BLINATUMOMAB (MT103) 128

FARLETUZUMAB (MORAB-003) . 128

EPRATUZUMAB 129

GIRENTUXIMAB (RENCAREX) 129

INOTUZUMAB OZOGAMICIN (CMC-544) 130

BRIAKINUMAB (ABT-874) . 131

ELOTUZUMAB 132

SILTUXIMAB (CNTO 328) 133

TRASTUZUMAB EMTANSINE (T-DM1, RG3502) 133

INOLIMOMAB (LEUKOTAC) . 134

ITOLIZUMAB (T1H, ANTI-CD6) 134

NAPTUMOMAB ESTAFENATOX (ANYARA) . 135

NECITUMUMAB (IMC-11F8) . 135

PERTUZUMAB 136

RAMUCIRUMAB (IMC-1121B, LY3009806) 137

RAXIBACUMAB 138

MK-3415, MK-6072, AND MK-3415A . 138

MK-3415, MK-6072, and MK-3415A (Continued) 139

CHAPTER SIX: APPLICATIONS 140

OVERVIEW . 140

TABLE 18 MONOCLONAL ANTIBODIES ON THE MARKET, BY

INDICATION 2011 (NUMBER/%) 140

TABLE 19 GLOBAL SALES OF THERAPEUTIC MONOCLONAL

ANTIBODIES, BY APPLICATION, THROUGH 2016 ($ MILLIONS) . 141

TABLE 20 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT, BY INDICATION, 2011 (NUMBER/%) . 141

TABLE 20 (CONTINUED) . 142

AUTOIMMUNE DISEASES 142

CROHN'S DISEASE 143

PSORIASIS . 144

RHEUMATOID ARTHRITIS . 145

TABLE 21 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (NOT INCLUDING MS), THROUGH 2016 ($ MILLIONS) . 145

SOLID TUMORS 146

U.S. CANCER STATISTICS 146

TABLE 22 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2011 . 147

TABLE 23 CANCER PREVALENCE RATES IN THE U.S., 2008 (IN THOUSANDS) . 148

BREAST CANCER . 149

COLORECTAL CANCER 149

HEAD AND NECK CANCER 149

KIDNEY CANCER . 149

LIVER CANCER 149

LUNG CANCER . 150

MALIGNANT MELANOMA 150

OSTEOSARCOMA . 151

OVARIAN CANCER 151

PANCREATIC CANCER . 152

PROSTATE CANCER 152

STOMACH CANCER . 153

ANTIBODY PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER . 153

TABLE 24 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF SOLID TUMORS, BY REGION, THROUGH 2016 ($ MILLIONS) . 153

LYMPHOMAS AND LEUKEMIAS 153

NON-HODGKIN LYMPHOMA . 154

LEUKEMIAS 154

Leukemias (Continued) . 155

CARDIOVASCULAR DISEASES 156

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY 157

INFECTIOUS DISEASES 158

CYTOMEGALOVIRUS INFECTION 159

HEPATITIS 160

RESPIRATORY SYNCYTIAL VIRUS INFECTION 160

TABLE 25 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFECTIOUS DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 161

MULTIPLE SCLEROSIS . 161

TABLE 26 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, BY REGION, THROUGH 2016 ($ MILLIONS) . 162

OPHTHALMIC DISEASES 162

MACULAR DEGENERATION 162

OTHER THERAPEUTIC APPLICATIONS . 163

TABLE 27 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF OTHER DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 163

CHAPTER SEVEN: INDUSTRY STRUCTURE . 164

OVERVIEW . 164

ORIGINATORS . 164

COMMERCIAL DEVELOPERS . 165

VENDORS . 166

MANUFACTURERS . 166

TECHNOLOGY INNOVATORS. 167

PRICING FORECASTS 168

THE REGULATORY ENVIRONMENT 168

THE REGULATORY ENVIRONMENT (CONTINUED) . 169

GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS . 170

GENOMICS AND MONOCLONAL … (CONTINUED) . 171

GENOMICS AND MONOCLONAL … (CONTINUED) . 172

COMPANY SALES AND MARKET SHARE . 173

TABLE 28 SALES OF MARKETED ANTIBODIES BY

MANUFACTURER, THROUGH 2016 ($ MILLIONS) 174

TABLE 29 MANUFACTURERS OF ANTIBODIES BY MARKET SHARE, 2011 AND 2016 (%) 175

TABLE 30 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY COMPANY . 176

COMPANY PROFILES 176

ABBOTT LABORATORIES . 176

ALEXION PHARMACEUTICALS 177

AMGEN 178

ASTRAZENECA . 179

AstraZeneca – U.S. Headquarters 179

BAYER AG . 180

Bayer (U.S. Location) 180

BIOGEN IDEC . 181

BRISTOL-MYERS SQUIBB 182

BTG . 183

DAIICHI SANKYO . 183

ELAN 184

EMERGENT BIOSOLUTIONS . 185

EISAI 185

ELI LILLY 186

GENMAB 186

Genmab (U.S. Location) 187

GLAXOSMITHKLINE . 187

GlaxoSmithKline (U.S. Location) 187

HUMAN GENOME SCIENCES 188

JOHNSON & JOHNSON . 188

KALOBIOS PHARMACEUTICALS 189

MERCK KGAA (MERCK SERONO) . 190

MORPHOSYS . 191

NOVARTIS . 191

PFIZER . 192

ROCHE . 193

To order this report:Biopharmaceutical Industry: Antibody Drugs: Technologies and Global Markets

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Drug Ads Often Gloss Over Side Effects, Enlist Doctor Endorsements

Wed, 23 May 2012 07:12:32 +0000

Drug company advertising often downplays side effects. This misleading information can lead to patient injury.

May 23, 2012 /24-7PressRelease/ -- Prescription drug advertisements have become ubiquitous in United States' media, including television and magazines. Unfortunately, these ads may be ultimately misleading about potential side effects, placing patients at risk.

How Drug Marketing Campaigns Portray Side Effects

Drug companies use several techniques to downplay the side effects of the potentially dangerous drugs they are advertising.

First, a drug company may enlist a celebrity to endorse its product. For example, the anti-inflammatory drug Enbrel is promoted by professional golfer Phil Mikelson. In these types of advertisements, the side effects of the drugs are disclosed in a quickly delivered voiceover toward the end of the commercial. Other drug advertisements, like those for Celebrex, place a lot of emphasis on the benefits of the drug while downplaying serious side effects like heart attack or stroke.

Another common technique is enlisting the endorsement of an actual physician, who may agree to recommend drugs in exchange for board membership, lectureship and even consulting fees.

Doctors' Drug Endorsements Affect Patient Care

When doctors endorse a drug for money or other personal benefits, however, the exchange can affect the type of care patients receive. An investigation by the New York Times found that a quarter of all doctors accept cash for their endorsement of prescription drugs and a whopping two-thirds accept other compensation, like meals or speaking engagements, for endorsements.

Unfortunately, this type of relationship between physicians and drug companies can affect the medical decisions of the endorsing physicians. Physicians who endorse a certain medication are more likely to prescribe those medications when an alternative treatment would be more medically appropriate. In some instances, the New York Times found that physicians in this situation were more apt to prescribe antipsychotic drugs to children, for whom the drugs are not approved.

Obama's Health Care Law to Provide More Transparency

Fortunately, there are provisions in the new health care bill which will make the relationships between physicians and drug companies more transparent to the public. The law requires drug companies which pay doctors for endorsements for any drug or medical device covered by Medicare or Medicaid to report the relationships to the government. The Obama administration estimates that the law will affect over one thousand drug companies.

When drug companies downplay serious side effects which could cause injury, it leaves them vulnerable to lawsuits claiming they were negligent in their duty to warn against potential side effects. It may also be possible for injured patients to sue if a product is found to be defective. If you have been injured by one of your prescription drugs and feel you did not receive a clear explanation of the drug's potent side effects, please consult an experienced personal injury attorney to explore your legal options.

Article provided by Thomas Q. Keefe, Jr., P.C.

Visit us at http://www.tqkeefe.com/

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com

Winning The Battle Against Breast Cancer Metastasis

Tue, 22 May 2012 09:00:00 +0000

Winning The Battle Against Breast Cancer Metastasis

* Botanical formula slows highly invasive human breast cancer growth, reduces metastasis.

* Formula includes extracts from medicinal mushrooms and herbs and other natural compounds.

* No toxic side effects were detected.

PR Newswire

CHICAGO, May 22, 2012 /PRNewswire/ -- Scientists at Indiana University Health's Cancer Research Laboratory have found that a sophisticated botanical formula slows human breast cancer growth and inhibits breast to lung metastasis in mice. The formula contains extracts from medicinal mushrooms, medicinal herbs and purified nutritional compounds, and showed no toxic side-effects. These results were presented at the April 2012 American Association for Cancer Research Annual Meeting.

"Our results are very exciting because we clearly demonstrate the suppression of breast to lung cancer metastasis associated with the inhibition of specific pro-metastatic genes in human tumors," says Daniel Sliva, Ph.D., Associate Professor at the Indiana University School of Medicine and lead author on the study.

Researchers implanted highly invasive, triple-negative human breast cancer cells (MDA-MB-231) in mice, which were then given the formula orally for four weeks. The formula significantly decreased tumor growth and breast to lung metastasis. The cancer metastasized to the lungs in 70 percent of controls but only 20 percent of treated mice. The number of metastases per animal was also significantly reduced by the formula. Further study showed the formula down-regulates the primary tumor genes PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4), which have both been implicated in metastasis.

"Patients with breast cancer die from metastasis," said formula inventor and study co-author Isaac Eliaz, M.D. "This formula was able to change the gene expression of highly aggressive metastatic breast cancer and dramatically decrease the deadly metastatic process."

The formula uses a variety of natural compounds, each of which have demonstrated anti-cancer properties. Mycelium from medicinal mushrooms Coriolus versicolor, Ganoderma lucidum and Phellinus linteus reduced growth and invasiveness. Extracts from Scutellaria barbata, Astragalus membranaceus and Curcuma longa are known to induce programmed cell death (apoptosis) and reduced metastasis. The flavonoid quercetin reduced proliferation and helped suppress tumor growth. In addition, 3, 3'-Diindolylmethane (DIM), an active byproduct of cruciferous vegetable digestion, reduced cancer growth, migration and invasiveness.

"Here, we show that the formula is not toxic and its oral application significantly suppresses time-dependent increase in tumor sizes and
inhibits breast-to-lung cancer metastasis," says Dr. Sliva. "This formula may be considered as a biological therapeutic agent against invasive breast cancer, including the aggressive triple negative breast cancer. It can potentially increase survival of breast cancer
patients."

For more information on the breast health formula call (707) 583-8619, email info@betterhealthpublishing.com, or visit www.breasthealthsolutions.org

About Better Health Publishing:

Media Contacts:
For Media Questions/Interviews with Dr. Isaac Eliaz, Contact:
Better Health Publishing
info@betterhealthpublishing.com
(707) 583-8619

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

SOURCE Better Health Publishing

AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated

Mon, 21 May 2012 21:18:20 +0000

AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated

PR Newswire

BRANFORD, Conn., May 21, 2012 /PRNewswire/ -- HistoRx, the leader in quantitative immunohistochemistry, announces the application of their proprietary AQUA technology to assessment of messenger RNA in tissue. AQUA technology enables robust quantification and standardization of protein in tissue specimens; this new work extends the platform's capabilities beyond protein expression analysis to quantification of nucleic acids.

AQUA technology was invented to address the challenges of measuring protein in tissue with the same precision and reproducibility with which laboratories measure glucose in blood. Human tissue, particularly tumor tissue, is a highly complex environment in which a biomarker's location, quantity and heterogeneity can all be important factors in understanding the biology of the disease. The ability to use the strengths of AQUA technology to evaluate both protein and RNA allows researchers, for the first time, to explore their relationship within tumor tissue.

Messenger RNA (mRNA) is a nucleic acid that functions as blueprint to translate DNA's genetic code into proteins, the functional units of the cell. As a biomarker, it enables scientists to evaluate the step between the cell's genetic information and its protein expression. Assessment of mRNA is usually performed via RT-PCR, a highly sensitive technique that is not easily standardized. Yale University Professor of Pathology David Rimm, MD, PhD, and his collaborators have taken a new approach, combining AQUAnalysis® from HistoRx with RNAscope® from Advanced Cell Diagnostics, to gain crucial benefits. Dr. Rimm and his collaborators have completed an important study of mRNA by AQUA technology, published in this month's PLoS ONE as "Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen." The study of two independent breast cancer cohorts (n = 128 and n = 524) demonstrated that quantification of mRNA using AQUA technology and RNAscope together may allow sensitive, specific and reproducible measurement of mRNA in FFBE breast cancer tissues.

"The coupling of ACD's RNAscope with AQUA technology starts to address a critical unmet need in RNA quantification in tissue," said Yuling Luo, Ph.D., Founder, President and CEO of ACD. "Further, enabling the combination of RNA and protein quantification on the same tissue slide could provide a dynamic new view of physiology and cell signaling in tumor tissue."

Although mRNAs have been identified as important factors in cancer pathogenesis, their evaluation techniques typically require use of ground tissue, rather than intact specimens. As a result, the location of the analyte within the tissue is lost, and the generation of standardized results is jeopardized. Dr. Rimm, founding scientist of HistoRx and Director of Pathology Tissue Services at the Yale School of Medicine, explains: "This dual approach has the advantages of retaining critical spatial information while increasing throughput when used in combination with tissue microarrays. With internal standardization and spatial information, the accuracy of this test should exceed RT-PCR."

AQUA technology is an automated, quantitative fluorescent IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis. Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with conventional testing methods, such as standard immunohistochemistry (IHC). AQUA analysis is used in cancer research by more than twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 120 peer-reviewed publications. AQUA technology is currently available on the ScanScope® FL from Aperio and the Vectra™ 2 system from Caliper Life Sciences, a PerkinElmer company.

About HistoRx, Inc.

HistoRx, Inc. is the leader in quantitative immunohistochemistry and a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.

SOURCE HistoRx

LUNGevity Breathe Deep PSAs to Air During Indianapolis 500 Festivities, Race

Mon, 21 May 2012 14:41:42 +0000

LUNGevity Breathe Deep PSAs to Air During Indianapolis 500 Festivities, Race

PR Newswire

Nation's largest lung cancer-focused nonprofit asks viewers to help stop lung cancer now

WASHINGTON, May 21, 2012 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to announce its Public Service Announcements will play on the JumboTron during the May 25-27, 2012 Indy 500 festivities and race, in conjunction with May's designation as Lung Cancer Hope Month. The PSAs will promote awareness of the need for lung cancer research, inviting all Indianapolis Motor Speedway attendees to join in LUNGevity Breathe Deep events to raise awareness and funds for earlier detection and more effective treatments of lung cancer. LUNGevity's 60-second version (http://youtu.be/bEMl9JWw4mA) and a 30-second version PSAs (http://youtu.be/Si5b5jM7Cww) will both be featured.

The Breathe Deep walks and runs are LUNGevity's signature events that occur in dozens of communities nationwide. Breathe Deep events were launched by the Foundation to raise public awareness and critical funds needed for lung cancer research. One in 14 Americans is diagnosed with lung cancer in their lifetime. The disease kills almost twice as many women as breast cancer and more than three times as many men as prostate cancer. About 55% of all new lung cancer diagnoses are among people who have never smoked or are former smokers. Compared to other cancers, the disease receives relatively little government research funding.

"We are grateful for the opportunity to reach over 1.5 million viewers with our PSAs," said LUNGevity Foundation President Andrea Stern Ferris. "The PSAs capture the energy and spirit of those participating in Breathe Deep events, and we hope they inspire Indy 500 fans to take action, join us, and start their own events. LUNGevity is committed to finding early diagnoses and more effective treatments for lung cancer."

LUNGevity is the nation's largest lung cancer-focused nonprofit. It has the largest grants award program for lung cancer research among lung cancer nonprofit organizations in the United States. In 2011 alone, LUNGevity awarded $2 million to fund nine of the most promising lung cancer research proposals in the areas of early detection and targeted therapeutics. In addition to funding research, the Foundation has a robust national grassroots network, with events happening across the country. The organization also has the largest online support community for lung cancer patients and their loved ones.

The Foundation created Lung Cancer Hope Month, in May, to recognize the hope for better treatments and earlier diagnoses for lung cancer, improving lung cancer survival rates and quality of life for lung cancer patients and their loved ones. During the month, LUNGevity has hosted a number of events to build awareness of the lung cancer community and raise funds for critical lifesaving research. LUNGevity's presence at the Indy 500 will conclude an important month of community engagement for the organization.

To schedule an interview with LUNGevity Foundation President Andrea Stern Ferris, contact Victoria Shapiro at (202) 414-0774 or vshapiro@susandavis.com

About LUNGevity Foundation

The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.

Through the support of critical research into the early detection and successful treatment of lung cancer, as well as providing information, resources and a community to patients and caregivers, LUNGevity is creating and sharing hope for cures, treatments and enhanced quality of life for lung cancer patients.

LUNGevity seeks to inspire the nation to commit to ending lung cancer.

For more information, please visit www.lungevity.org.

About Lung Cancer

1 in 14 Americans is diagnosed with lung cancer in their lifetime
Lung cancer is the leading cause of cancer death, regardless of gender or ethnicity
Lung cancer kills almost twice as many women as breast cancer and more than three times as many men as prostate cancer
About 55 percent of all new lung cancer diagnoses are among people who have never smoked or are former smokers
Only 16 percent of all people diagnosed with lung cancer will survive 5 years or more, but if it's caught before it spreads, the chance for 5-year survival improves to 52 percent

SOURCE LUNGevity Foundation

Global Special Purpose Needles Industry

Mon, 21 May 2012 14:25:26 +0000

Global Special Purpose Needles Industry

PR Newswire

NEW YORK, May 21, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Special Purpose Needles Industry

http://www.reportlinker.com/p098381/Global-Special-Purpose-Needles-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_

This report analyzes the worldwide markets for Special Purpose Needles in US$ Million by the following Product Segments: Acupuncture Needles, Aspirating Needles, Biopsy Needles, Blood Collection Needles, Blunt Needles, Bone Marrow Needles, Cardiology Needles, Catheter Needles, Dental Needles, Dialysis Needles, Electrode Needles, Endoscopy Needles, Epidural Needles, Fistula Needles, Hypodermic Needles, Intra-arterial Needles, Intravenous Needles, Ophthalmic Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal Needles, and Suture Needles. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 150 companies including many key and niche players such as Angiotech Pharmaceuticals, Inc., Argon Medical Devices, Inc., Becton, Dickinson and Company, Becton Dickinson France S.A.S., B. Braun Medical, Inc., Cadence Science, CareFusion Corporation, Covidien Ltd., C. R. Bard, Inc., Bard Access Systems, Inc., Bard Biopsy Systems, Ethicon, Inc., Inrad, Inc., Medline Industries, Inc, MIFAM SA, Smiths Medical, TERUMO Corporation, and World Wide Medical Technologies. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

A. Acupuncture Needles I-4

B. Aspirating Needles I-4

C. Biopsy Needles I-5

D. Blood Collection Needles I-5

E. Blunt Needles I-5

F. Bone Marrow Needles I-5

G. Cardiology Needles I-5

H. Catheter Needles I-5

I. Dental Needles I-5

J. Dialysis Needles I-6

K. Electrode Needles I-6

L. Endoscopy Needles I-6

M. Epidural Needles I-6

N. Fistula Needles I-6

O. Hypodermic Needles I-6

P. Intra-arterial Needles I-7

Q. Intravenous Needles I-7

R. Ophthalmic Needles I-7

S. Pneumoperitoneum Needles I-7

T. Radiology Needles I-7

U. Spinal Needles I-7

V. Suture Needles I-7

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1

Special Purpose Needles Beat Recession II-1

2. MAJOR TRENDS & ISSUES II-2

Home and Alternate Healthcare Driving Growth of Disposable

Products II-2

Enhancing Demand for Safety Syringes II-2

Needleless Technologies Revolutionizing Insulin Drug Delivery

Market II-2

Medical Industries Seeking Ways to Prevent Needlestick Injuries II-2

Sales of Traditional Needles and Syringes to Shrivel II-3

Quality Issues Gain Importance II-3

3. PRODUCT OVERVIEW II-4

Needles - Definition II-4

Reusable Needles II-4

Disposable Needles II-4

Needles by Type II-4

Acupuncture Needles - Pricking Needles to Relieve Pain II-4

Anesthesia Needles II-5

Epidural Needles II-5

Spinal Needles II-5

Angiography Needles II-5

Aspirating Needles - Use of Needles for Aspiration II-6

Biopsy Needles - Imperative to Needle Biopsy II-6

Biopsy Procedures II-6

Used in Diagnosing Breast Cancer II-6

Needle Biopsy Substitutes Open Biopsy II-6

Needle Biopsies Vs Open Biopsies II-6

Fine-needle Aspiration Biopsy II-7

Advantages of Fine Needle Aspiration II-7

Blood Collection Needles II-7

Blood Collection Process - Use of Phlebotomy Needles II-7

Blunt Needles II-8

Bone Marrow Needles II-8

Cardiology Needles II-8

Catheter Needles II-8

Dental Needles II-8

Dental Professionals Favor Disposables II-9

Dialysis Needles II-9

The Hemodialysis Process II-9

Electrode Needles II-9

Surface Electrodes II-10

Passive Electrode II-10

Active Electrode II-10

Needle Electrodes II-10

Wire Electrodes II-10

Endoscopy Needles II-11

Fistula Needles II-11

Hypodermic Needles II-11

Intravenous Needles II-11

Ophthalmic Needles II-12

Pneumoperitoneum Needles II-12

Radiology Needles II-12

Suture Needles - As Wound Closure Products II-12

Essential Qualities of a Suture Needle II-12

Classification of Suture Needles II-13

Based on Type of End II-13

Swaged Needles II-13

Eyed Needles II-13

Based on Type of Body II-13

Straight Needles II-13

Curved Needles II-13

Half-curved Needles II-13

Compound Curved Needles II-14

Other Needles II-14

Applications of Needles II-14

Stereotactic Radiotherapy II-14

Brachytherapy - Use of Hollow Needles for Treating Prostrate

Cancer II-14

Electrochemotherapy: An Application Area for Needles II-14

Role of Needles in Transmission of Blood-Borne Disease II-15

Overcoming Complications Arising Due to Frequent Needle Insertion II-15

4. MEASURES FOR CHECKING NEEDLESTICK INJURIES II-16

Prevention of Needle Stick Injuries II-16

Use of Safety Devices II-16

Safety Connection Systems II-17

Port Primers - An Important Part In Safety Connection Systems II-17

Types of Safety Connection Systems II-17

Protected Needles Connected to a Standard Injection Port II-17

Blunt Plastic Cannulae Connected to a Pre-slit Port II-17

Male Leur Tip with Leur-Activated Valve II-18

One-Piece, Swabable Leur-Activated Valve II-18

5. NEEDLE EXCHANGE PROGRAMS II-19

Supply of Needles and Syringes - The Legal Aspect II-20

The Federal Mail Order Drug Paraphernalia Control Act II-20

Syringe Prescription Statutes II-20

Pharmacy Regulations and Practice Guidelines II-20

Regulations for Health Professionals II-20

6. DISPOSAL/DISTRIBUTION II-21

Disposal of Needles and Syringes - A Menace II-21

Medical and Surgical Supply Industry Consolidates II-21

Channels of Distribution II-21

End-Outlets of Needles II-21

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-22

Ethicon Launches Ethiguard Blunt Point Needles for Preventing

Needlestick Injuries II-22

BD Diagnostics Launches Passive Shielding Blood Collection

Needles II-22

Cook Medical Unveils New Line of High Definition EUS Biopsy

Needles II-22

Unimed Rolls Out Reusable Needles II-23

Roydent Introduces 'Memory Shape' Endodontic Reusable NiTi Needle II-23

Spetodont Launches Septoject XL Needles II-23

SURU International Unveils IV Cannulae II-23

Practicon Unveils Extra-Short Needles for Dental Applications II-23

BD Medical Unveils BD AutoShield™ Pen Needle II-24

Collagen Matrix Launches Multiport Bone Marrow Aspiration Needle II-24

Akray Launches Naturalet Blood Collection Needle Line II-24

Smiths Medical Offers GRIPPER PLUS® Safety Needles with

Needlestick Safety II-24

Smiths Medical Launches Pencil and Lancet Point Needles II-24

Smiths Medical Unleashes ProBloc® S Nerve Block Needles II-25

CIVCO Medical Launches Needle Guidance System for GE's Transducer II-25

SHPI Unleashes MiniLoc™ and SecureLoc™ Needle II-25

Novo Nordisk Develops Safety Needle for Healthcare Providers II-25

Novo Nordisk Launches NovoFine® 32G Tip needle II-25

Researchers Develop New Dendrimer Material as an Alternative

to Hypodermic Needles II-25

8. RECENT INDUSTRY ACTIVITY II-26

Revolutions Medical Inks MOU with Santa Monica Pharmaceutica II-26

Nanoscience Instruments Commences Global Distribution of New

NaugaNeedles Line II-26

Braun Medical Signs Supply Agreement with Health Trust II-26

Havel's Incorporated Signs Partnership with CHS to Distribute

its Ultrasound Needles in Canada II-27

Specialty Blades Completes Acquisition of Popper and Sons II-27

Theragenics Snaps Up NeedleTech Products II-28

NxStage Medical and DaVita Enter into Supply Agreement for

Needles II-28

Smiths Medical Bags Safety Needlesticks Contract II-28

C.R. Bard Acquires SHPI II-28

Miltex Bags Product Distribution Rights II-29

9. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER II-30

Smiths Medical Bags FDA Approval for GRIPPER® Micro Safety Needle II-30

Greatbatch Acquires Enpath II-30

SHPI Inks Agreement with B.Braun Medical II-30

Cardinal Health Pockets VIASYS II-30

NxStage Medical Acquires Medisystems II-30

Neogen Pockets Rivard Instruments II-31

Terumo Expands Production Capacity II-31

Telezon Establishes New Laboratory II-31

Angiotech Pharmaceuticals Purchases AMI for $785M II-31

Devon Medical's SharpShield™ Safety Syringe Clears FDA Hurdle II-31

SHPI Concludes Merger with Med-Design Corp II-31

Inviro Medical Partners VON to Launch InviroSNAP!® Safety Syringe II-32

SHPI Secures Patent For MiniLoc™ II-32

Viasys Acquires Medical Business Oxford Instruments of UK II-32

SHPI Signs Multiple Agreements for Safety Needle Products II-32

PneumRx Obtains FDA Approval for Biopsy Needles and Kits II-32

Orthovita Obtains FDA Nod for Imbibe™ BMA Needle II-32

10. FOCUS ON SELECT KEY PLAYERS II-33

Angiotech Pharmaceuticals, Inc. II-33

Argon Medical Devices, Inc. (US) II-33

Becton, Dickinson and Company (US) II-33

Becton Dickinson France S.A.S. (France) II-34

B. Braun Medical, Inc. (US) II-34

Cadence Science (US) II-34

CareFusion Corporation (US) II-35

Covidien Ltd. (US) II-35

C. R. Bard, Inc. (US) II-36

Bard Access Systems, Inc. (US) II-36

Bard Biopsy Systems (US) II-36

Ethicon, Inc. (US) II-36

Inrad, Inc. (US) II-37

Medline Industries, Inc (US) II-37

MIFAM SA (Poland) II-37

Smiths Medical (UK) II-38

TERUMO Corporation (Japan) II-38

World Wide Medical Technologies (US) II-38

11. GLOBAL MARKET PERSPECTIVE II-39

Table 1: World Recent Past, Current & Future Analysis for

Special Purpose Needles by Geographic Region/Country - US,

Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-39

Table 2: World Historic Review for Special Purpose Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-40

Table 3: World 15-Year Perspective for Special Purpose Needles

by Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-41

Table 4: World Recent Past, Current & Future Analysis for

Acupuncture Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-42

Table 5: World Historic Review for Acupuncture Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-43

Table 6: World 15-Year Perspective for Acupuncture Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-44

Table 7: World Recent Past, Current & Future Analysis for

Aspirating Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-45

Table 8: World Historic Review for Aspirating Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-46

Table 9: World 15-Year Perspective for Aspirating Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-47

Table 10: World Recent Past, Current & Future Analysis for

Biopsy Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-48

Table 11: World Historic Review for Biopsy Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-49

Table 12: World 15-Year Perspective for Biopsy Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia- Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-50

Table 13: World Recent Past, Current & Future Analysis for

Blood Collection Needles by Geographic Region/Country - US,

Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-51

Table 14: World Historic Review for Blood Collection Needles

by Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-52

Table 15: World 15-Year Perspective for Blood Collection

Needles by Geographic Region/Country - Percentage Breakdown of

Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-53

Table 16: World Recent Past, Current & Future Analysis for

Blunt Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-54

Table 17: World Historic Review for Blunt Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-55

Table 18: World 15-Year Perspective for Blunt Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-56

Table 19: World Recent Past, Current & Future Analysis for

Bone Marrow Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-57

Table 20: World Historic Review for Bone Marrow Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-58

Table 21: World 15-Year Perspective for Bone Marrow Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-59

Table 22: World Recent Past, Current & Future Analysis for

Cardiology Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-60

Table 23: World Historic Review for Cardiology Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-61

Table 24: World 15-Year Perspective for Cardiology Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-62

Table 25: World Recent Past, Current & Future Analysis for

Catheter Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-63

Table 26: World Historic Review for Catheter Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-64

Table 27: World 15-Year Perspective for Catheter Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-65

Table 28: World Recent Past, Current & Future Analysis for

Dental Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-66

Table 29: World Historic Review for Dental Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-67

Table 30: World 15-Year Perspective for Dental Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia- Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-68

Table 31: World Recent Past, Current & Future Analysis for

Dialysis Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-69

Table 32: World Historic Review for Dialysis Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-70

Table 33: World 15-Year Perspective for Dialysis Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia- Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-71

Table 34: World Recent Past, Current & Future Analysis for

Electrode Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-72

Table 35: World Historic Review for Electrode Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-73

Table 36: World 15-Year Perspective for Electrode Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia- Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-74

Table 37: World Recent Past, Current & Future Analysis for

Endoscopy Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-75

Table 38: World Historic Review for Endoscopy Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-76

Table 39: World 15-Year Perspective for Endoscopy Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-77

Table 40: World Recent Past, Current & Future Analysis for

Epidural Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-78

Table 41: World Historic Review for Epidural Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-79

Table 42: World 15-Year Perspective for Epidural Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-80

Table 43: World Recent Past, Current & Future Analysis for

Fistula Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-81

Table 44: World Historic Review for Fistula Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-82

Table 45: World 15-Year Perspective for Fistula Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-83

Table 46: World Recent Past, Current & Future Analysis for

Hypodermic Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-84

Table 47: World Historic Review for Hypodermic Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-85

Table 48: World 15-Year Perspective for Hypodermic Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-86

Table 49: World Recent Past, Current & Future Analysis for

Intra-arterial Needles by Geographic Region/Country - US,

Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-87

Table 50: World Historic Review for Intra-arterial Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-88

Table 51: World 15-Year Perspective for Intra-arterial Needles

by Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-89

Table 52: World Recent Past, Current & Future Analysis for

Intravenous Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-90

Table 53: World Historic Review for Intravenous Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-91

Table 54: World 15-Year Perspective for Intravenous Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-92

Table 55: World Recent Past, Current & Future Analysis for

Ophthalmic Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-93

Table 56: World Historic Review for Ophthalmic Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-94

Table 57: World 15-Year Perspective for Ophthalmic Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-95

Table 58: World Recent Past, Current & Future Analysis for

Pneumoperitoneum Needles by Geographic Region/Country - US,

Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-96

Table 59: World Historic Review for Pneumoperitoneum Needles

by Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-97

Table 60: World 15-Year Perspective for Pneumoperitoneum

Needles by Geographic Region/Country - Percentage Breakdown of

Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-98

Table 61: World Recent Past, Current & Future Analysis for

Radiology Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-99

Table 62: World Historic Review for Radiology Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-100

Table 63: World 15-Year Perspective for Radiology Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-101

Table 64: World Recent Past, Current & Future Analysis for

Spinal Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-102

Table 65: World Historic Review for Spinal Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-103

Table 66: World 15-Year Perspective for Spinal Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-104

Table 67: World Recent Past, Current & Future Analysis for

Suture Needles by Geographic Region/Country - US, Canada,

Japan, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-105

Table 68: World Historic Review for Suture Needles by

Geographic Region/Country - US, Canada, Japan, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-106

Table 69: World 15-Year Perspective for Suture Needles by

Geographic Region/Country - Percentage Breakdown of Value

Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-107

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Demand for Safety Needles on Rise III-1

Factors Driving Growth in Needle and Syringe Markets III-1

Pen Needles - Writing a New Chapter in Insulin Delivery III-1

B.Market Analytics III-2

Table 70: US Recent Past, Current & Future Analysis for

Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-2

Table 71: US Historic Review for Special Purpose Needles by

Product Segment-Acupuncture Needles, Aspirating Needles,

Biopsy Needles, Blood Collection Needles, Blunt Needles,

Bone Marrow Needles, Cardiology Needles, Catheter Needles,

Dental Needles, Dialysis Needles, Electrode Needles,

Endoscopy Needles, Epidural Needles, Fistula Needles,

Hypodermic Needles, Intra-arterial Needles, Intravenous

Needles, Ophthalmic Needles, Pneumoperitoneum Needles,

Radiology Needles, Spinal Needles and Suture Needles Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-4

Table 72: US 15-Year Perspective for Special Purpose Needles

by Product Segment - Percentage Breakdown of Value Sales for

Acupuncture Needles, Aspirating Needles, Biopsy Needles,

Blood Collection Needles, Blunt Needles, Bone Marrow

Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-6

2. CANADA III-7

Market Analytics III-7

Table 73: Canadian Recent Past, Current & Future Analysis

for Special Purpose Needles by Product Segment- cupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-7

Table 74: Canadian Historic Review for Special Purpose

Needles by Product Segment-Acupuncture Needles, Aspirating

Needles, Biopsy Needles, Blood Collection Needles, Blunt

Needles, Bone Marrow Needles, Cardiology Needles, Catheter

Needles, Dental Needles, Dialysis Needles, Electrode

Needles, Endoscopy Needles, Epidural Needles, Fistula

Needles, Hypodermic Needles, Intra-arterial Needles,

Intravenous Needles, Ophthalmic Needles, Pneumoperitoneum

Needles, Radiology Needles, Spinal Needles and Suture

Needles Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-9

Table 75: Canadian 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-11

3. JAPAN III-12

Market Analytics III-12

Table 76: Japanese Recent Past, Current & Future Analysis

for Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, B lunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needle Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-12

Table 77: Japanese Historic Review for Special Purpose

Needles by Product Segment-Acupuncture Needles, Aspirating

Needles, Biopsy Needles, Blood Collection Needles, Blunt

Needles, Bone Marrow Needles, Cardiology Needles, Catheter

Needles, Dental Needles, Dialysis Needles, Electrode

Needles, Endoscopy Needles, Epidural Needles, Fistula

Needles, Hypodermic Needles, Intra-arterial Needles,

Intravenous Needles, Ophthalmic Needles, Pneumoperitoneum

Needles, Radiology Needles, Spinal Needles and Suture

Needles Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-14

Table 78: Japanese 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-16

4. EUROPE III-17

Market Analytics III-17

Table 79: European Recent Past, Current & Future Analysis

for Special Purpose Needles by Geographic Region/Country -

France, Germany, UK, Italy, Spain, Russia and Rest of Europe

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-17

Table 80: European Historic Review for Special Purpose

Needles by Geographic Region/Country - France, Germany, UK,

Italy, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-18

Table 81: European Recent Past, Current & Future Analysis

for Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-19

Table 82: European Historic Review for Special Purpose

Needles by Product Segment-Acupuncture Needles, Aspirating

Needles, Biopsy Needles, Blood Collection Needles, Blunt

Needles, Bone Marrow Needles, Cardiology Needles, Catheter

Needles, Dental Needles, Dialysis Needles, Electrode

Needles, Endoscopy Needles, Epidural Needles, Fistula

Needles, Hypodermic Needles, Intra-arterial Needles,

Intravenous Needles, Ophthalmic Needles, pneumoperitoneum

Needles, Radiology Needles, Spinal Needles and Suture

Needles Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-21

Table 83: European 15-Year Perspective for Special Purpose

Needles by Geographic Region/Country - Percentage Breakdown

of Value Sales for France, Germany, Italy, UK, Spain, Russia

and Rest of Europe Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-23

Table 84: European 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-24

4a. FRANCE III-25

Market Analytics III-25

Table 85: French Recent Past, Current & Future Analysis for

Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-25

Table 86: French Historic Review for Special Purpose Needles

by Product Segment-Acupuncture Needles, Aspirating Needles,

Biopsy Needles, Blood Collection Needles, Blunt Needles,

Bone Marrow Needles, Cardiology Needles, Catheter Needles,

Dental Needles, Dialysis Needles, Electrode Needles,

Endoscopy Needles, Epidural Needles, Fistula Needles,

Hypodermic Needles, Intra- arterial Needles, Intravenous

Needles, Ophthalmic Needles, Pneumoperitoneum Needles,

Radiology Needles, Spinal Needles and Suture Needles Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-27

Table 87: French 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-29

4b. GERMANY III-30

Market Analytics III-30

Table 88: German Recent Past, Current & Future Analysis for

Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra- arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-30

Table 89: German Historic Review for Special Purpose Needles

by Product Segment-Acupuncture Needles, Aspirating Needles,

Biopsy Needles, Blood Collection Needles, Blunt Needles,

Bone Marrow Needles, Cardiology Needles, Catheter Needles,

Dental Needles, Dialysis Needles, Electrode Needles,

Endoscopy Needles, Epidural Needles, Fistula

Needles,Hypodermic Needles, Intra- arterial Needles,

Intravenous Needles, Ophthalmic Needles, Pneumoperitoneum

Needles, Radiology Needles, Spinal Needles and Suture

Needles Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-32

Table 90: German 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-34

4c. ITALY III-35

Market Analytics III-35

Table 91: Italian Recent Past, Current & Future Analysis for

Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles,Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-35

Table 92: Italian Historic Review for Special Purpose

Needles by Product Segment-Acupuncture Needles, Aspirating

Needles, Biopsy Needles, Blood Collection Needles, Blunt

Needles, Bone Marrow Needles, Cardiology Needles, Catheter

Needles, Dental Needles, Dialysis Needles, Electrode

Needles, Endoscopy Needles, Epidural Needles, Fistula

Needles, Hypodermic Needles, Intra-arterial Needles,

Intravenous Needles, Ophthalmic Needles, Pneumoperitoneum

Needles, Radiology Needles, Spinal Needles and Suture

Needles Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-37

Table 93: Italian 15-Year Perspective for Special Purpose

Needles by Product Segment - Percentage Breakdown of Value

Sales for Acupuncture Needles, Aspirating Needles, Biopsy

Needles, Blood Collection Needles, Blunt Needles, Bone

Marrow Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-39

4d. THE UNITED KINGDOM III-40

Market Analytics III-40

Table 94: UK Recent Past, Current & Future Analysis for

Special Purpose Needles by Product Segment-Acupuncture

Needles, Aspirating Needles, Biopsy Needles, Blood

Collection Needles, Blunt Needles, Bone Marrow Needles,

Cardiology Needles, Catheter Needles, Dental Needles,

Dialysis Needles, Electrode Needles, Endoscopy Needles,

Epidural Needles, Fistula Needles, Hypodermic Needles,

Intra-arterial Needles, Intravenous Needles, Ophthalmic

Needles, Pneumoperitoneum Needles, Radiology Needles, Spinal

Needles and Suture Needles Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-40

Table 95: UK Historic Review for Special Purpose Needles by

Product Segment-Acupuncture Needles, Aspirating Needles,

Biopsy Needles, Blood Collection Needles, Blunt Needles,

Bone Marrow Needles, Cardiology Needles, Catheter Needles,

Dental Needles, Dialysis Needles, Electrode Needles,

Endoscopy Needles, Epidural Needles, Fistula Needles,

Hypodermic Needles, Intra-arterial Needles, Intravenous

Needles, Ophthalmic Needles, Pneumoperitoneum Needles,

Radiology Needles, Spinal Needles and Suture Needles Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-42

Table 96: UK 15-Year Perspective for Special Purpose Needles

by Product Segment - Percentage Breakdown of Value Sales for

Acupuncture Needles, Aspirating Needles, Biopsy Needles,

Blood Collection Needles, Blunt Needles, Bone Marrow

Needles, Cardiology Needles, Catheter Needles, Dental

Needles, Dialysis Needles, Electrode Needles, Endoscopy

Needles, Epidural Needles, Fistula Needles, Hypodermic

Needles, Intra-arterial Needles, Intravenous Needles,

Ophthalmic Needles, Pneumoperitoneum Needles, Radiology

Needles, Spinal Needles and Suture Needles Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-44

4e. SPAIN

To order this report:

In Vitro Diagnostic Industry: Global Special Purpose Needles Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Global Herbal Supplements and Remedies Industry

Mon, 21 May 2012 14:22:49 +0000

Global Herbal Supplements and Remedies Industry

PR Newswire

NEW YORK, May 21, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Herbal Supplements and Remedies Industry

http://www.reportlinker.com/p080429/Global-Herbal-Supplements-and-Remedies-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_a

This report analyzes the worldwide markets for Herbal Supplements and Remedies in US$ Million by the following Product Segments: Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal Supplements. The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 108 companies including many key and niche players such as Amerifit Brands, Inc., Arizona Natural Products, Inc., Arkopharma SA, Bio-Botanica, Inc., Blackmores Ltd., Emami Ltd, Himalaya Drug Company, Imperial Ginseng Products Ltd., Indfrag Ltd., International Vitamin Corp [IVC], MMS Pro Professional Products, Natrol, Inc., Nature's Answer, Nature's Sunshine Products, Inc., NBTY, Inc., Sundown Nutrition, Nutraceutical International Corporation, Pharma Nord APS, Pharmaton Natural Health Products, Pharmavite® LLC, Potters Herbal Medicines, Ricola USA Inc, TwinLab Corporation, and Nature's Herbs. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Product Definitions I-4

Ginkgo Biloba I-4

Garlic I-4

Ginseng I-4

Echinacea I-4

St. John's Wort I-4

Soy I-4

Aloe Vera I-5

Specialty Herbs I-5

Multi-Herbs I-5

Other Herbal Supplements I-5

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET ANALYSIS II-1

Herbal Supplements and Remedies Defy Recession II-1

Herbs on the Positive Note II-1

Botanical Supplements Find a Niche in Functional Foods II-2

Sustainability - A Prime Concern II-2

Regional Landscape II-2

Prospects and Challenges of Dietary Supplements II-3

What Differentiates Herbals From Pharmaceuticals - A

Comparative Analysis II-3

Herbal Supplements Market II-3

Demographics - Playing a Major Role II-4

Table 1: Dietary Supplements Market Worldwide (2008):

Percentage Preference by Gender and Age Group (includes

corresponding Graph/Chart) II-4

Natural Herbalism - A Global Perspective II-5

Table 2: Worldwide Health and Wellness Market (2009 & 2010):

Percentage Breakdown of Leading Categories-Functional

fortified foods & beverages, Vitamins, minerals, herbal &

dietary supplements, Organic foods and beverages, Natural

foods and beverages and Personal care (includes corresponding

Graph/Chart) II-5

Table 3: Herbal Supplements Market Worldwide (2009):

Percentage Breakdown of Treatment Procedures for Western

Herbalism, Traditional Chinese Medicines, Homeopathy and

Ayurveda (includes corresponding Graph/Chart) II-6

Table 4: Leading Brands in the Global Soymilk Market (2008):

Percentage Share Breakdown for Silk, Silk Light, 8th

Continent, Silk Plus, Lifeway, Private label and Others

(includes corresponding Graph/Chart) II-6

Natural Medicine Acceptance Increases as Standard Chemical

Remedies Lose Appeal II-7

Botanical Products II-7

The Other Side - Herbal Remedies Endangering Wild Plant Species II-8

2. MARKET TRENDS & ISSUES II-9

Demand for Natural Health and Food Supplements on the Rise II-9

Functional Foods Market - Product Strategies Being Redefined II-9

Multi-Herbal Products on the Rise II-9

Ayurvedic Supplements Go Mainstream II-9

Reasons for Cheer II-10

Women's Healthcare Needs Propel Market II-10

Rising Concerns of Herbal Supplements II-11

Laboratory Studies Challenge Safety of Herbal Supplements II-11

Adverse Effects of Herbal Supplements- A Case Study II-11

Herbal Supplements and Prescription Drugs II-12

Herbal supplements and Breast Cancer II-12

Impact of Herbal Supplements on Patients Undergoing Plastic

Surgery II-12

Herbal Remedies & Arthritis Patients II-12

Impact of Media on the Herbs II-13

Lack of Brand Loyalty - Improves Private Label Category II-13

Specialty Products - A Booming Market II-13

3. PRODUCT OVERVIEW II-14

Herbal Supplements - Definition II-14

History II-14

Rise and Fall in American Herbalism II-15

Oriental and Ayurvedic Influences II-15

Product Segments/Sub-Segments II-16

Ginkgo Biloba - Oldest Living Tree Species II-16

Garlic - Spice of Life! II-16

Ginseng (Panax) - Multitude of Benefits II-16

Echinacea - The American Cone Flower II-17

Echinacea Augustifolia II-17

St. John's Wort - Aromatic Health II-18

Soy II-18

Aloe Vera II-18

Cat's Claw II-18

Kava II-19

Saw Palmetto - Men's Herbal Formula II-19

Saw Palmetto Found to Alleviate Urinary Tract Problems in Men II-19

Specialty Herbs II-20

Black Cohosh II-20

Green Tea II-20

Milk Thistle II-20

Schisandra II-20

Valerian II-20

Yohimbe II-20

Other Herbal Supplements II-21

4. DISTRIBUTION AND RETAIL STRUCTURE II-26

Health Food Stores II-26

Mass Merchandisers II-26

Other Key Distribution Channels II-26

5. EFFICACY AND SIDE EFFECTS OF HERBAL SUPPLEMENTS II-27

Are Herbal Supplements Really Effective? II-27

Side Effects II-27

Reality Check II-28

FDA Bans Ephedra Supplements II-28

Chaparral II-28

Penntroyal II-28

Quality Roadblocks for Herbal Supplements II-28

Ban on Kava Products II-28

MHUPO Prohibits Kava-Kava Sale II-28

Health Canada Bans Kava-Kava II-29

FSAI Orders Removal of 10 Herbal Supplement Products II-29

6. PRODUCT INTRODUCTIONS/INNOVATIONS II-30

Solbar Industries to Introduce Solpro 735 II-30

Rectory Foods Introduces New Garlic Range II-30

Jan Dekker Introduces Aloe Con Up 200 II-30

Lactiful Launches Lactiful CapsulesTM II-30

Bliss Ayurveda Introduces Ayurvedic Herbal Supplements II-31

Hamdard Laboratories Introduces Jigreen II-31

Biotropics to Unveil New Health Products II-31

Solae Launches SUPRO® XF II-31

Gaia Herbs Introduces Acai Berry Liquid Phyto-capTM II-32

Naturally Nova Scotia Launches Echinacea Throat Spray II-32

GreenDog Naturals Unveils Complete Calm II-32

GX International Launches GluControl II-33

Murad Introduces Pomegranate Mask II-33

Livethesource Introduces Nano-Encapsulated Supplement II-33

MediHerb Introduces Endocrine Essentials II-33

MediHerb Launches Adrenal II-34

Biostar Introduces New Products II-34

ONE Bio Unveils Complete Beauty and Treatment Series II-34

RZN Nutraceuticals To Launch HerbaZorb Technology II-34

Hindustan Latex Partners with Kottakal to Launch Women's

Ayurvedic Products II-34

Bionorica Launches Sinupret® Monograph II-35

Hickman Health Launches an All Natural BeeReady II-35

RevGenetics Launches Nitro250 II-35

Soy Labs Unveils Peptide Product LunaSoy and Lunasin II-35

Nature's Answer® Launches Orac Super 7™ Wafers and Capsules II-36

Nature's Answer® Launches Chia seeds and Chia Meal II-36

ACME Laboratories Introduces Acme's SPIRULINA II-36

ACME Laboratories Introduces GINGO and HEPAMILK II-36

Nature Made® Introduces Two More Liquid Softgels II-36

Pharmative Launches Nature Made's Cholesterol Combating Products II-37

Nature Made® Launches SAM-e Complete™ II-37

SOYJOY® Launches New SOYJOY Bars II-37

RevGenetics Unveils Sirtuin Skin II-37

Reliv International Introduces GlucAffect™ II-37

Enzymatic Therapy®, Launches DGL ULTRA II-38

OOKISA Launches OOKISA Hair Thickening Systéme (US) II-38

O Organics™ Introduces Organic Supplements II-38

Karnataka Soaps and Detergents Introduces New Products (India) II-38

Guru Energy Drink Introduces Juicy Superfruit and Full On

Lemonade Flavors II-39

Anglo-French Drugs and Industries to Introduce Assortment of

Herbal Products II-39

Moleac Introduces NeuroAid10 in the US II-39

7. PRODUCT INNOVATIONS IN RECENT PAST - A PERSPECTIVE BUILDER II-40

Bioponic Phytoceuticals Launches an All Natural Baby Product

Suite II-40

Costa and Company Launches Water in Herbal Flavors II-40

Pharmavite Launches Double Strength Fish Oil II-40

8. RECENT INDUSTRY ACTIVITY II-41

DSM Nutritional Products Acquires Martek II-41

CHS Enters into Agreement to Acquire Solbar II-41

Mistral Ventures Acquires Nature's Bioceuticals II-42

Martek Biosciences Acquires Amerifit II-42

Inverness Medical Innovations Divests Dietary Supplement Business II-42

The Carlyle Group Acquires NBTY II-42

Mark T. Wendell Tea Acquires Grace Tea II-42

BioPharm Asia Acquires Tonghua Tianbao Wood Frog Cultivation II-43

Rohto Pharmaceutical Enters into Joint Venture with Uchida

Wakanyaku and Chinese Company II-43

National Pharmaceutical Signs Letter of Intent with Vida

Pharma International II-43

Atrium Innovations Acquires Trophic Canada II-43

Baywood International to Sell Nutritional Specialties to Nutra II-44

Herbalife Acquires Specific Assets of Micelle Laboratories II-44

Novus Int`l Arenus Takes Over Equilite II-44

Tessenderlo Kerley Acquires Linuron Herbicide Enterprise of

DuPont II-44

Bayer's Innovative Cross Licensing Agreements II-45

Fresh Harvest Enters into an Agreement with Pharma Health II-45

US Farms Enters into Distribution Partnership with Natures Best II-45

Avesthagen to Expand its Herbal Supplements Food Business in

India II-45

Vanguard Pharmaceutical Acquires Swine Guard II-46

Town Health International to Acquire Max Goodrich II-46

Berje Acquires Whole Herb Company II-46

TNC Acquires Trimlife II-46

Genesis Acquires Hongrui II-47

Atrium Innovations Takes over Nutri-Health Supplements II-47

Valensa International Collaborates with Parry Nutraceuticals II-47

Emami Ltd Acquired Zandu Pharmaceutical Works Ltd. II-48

Valensa International and Parry Nutraceuticals Jointly Launch

SpiruZan™ II-48

Emerson Ecologics Acquires TIDhealth II-48

Indoco Acquires Shree Herbal Technologies II-48

Jilin Zixin Pharmaceutical to Acquire Jilin Caohuandan

Pharmaceutical II-48

Innosis Ecological Acquires Heng Run Xiong Fang Nano Technology II-48

Nature's Way Holding to Acquire Enzymatic Therapy II-49

Naturex Acquires Actifs Innovants Unit of Berkem II-49

NBTY Acquires Leiner Health Products II-49

China Sky One Medical Acquires Heilongjiang Haina Pharmaceutical II-49

Tongjitang Chinese Medicines Signs Agreement with Qinghai

Pulante Pharmaceutical II-50

China Aoxing Pharma Acquires Shijiazhuang Lerentang

Pharmaceutical II-50

Dr. Willmar Schwabe Acquires MH Pharma II-50

Herbalife Expands Operations II-51

Vitamin Shoppe to Purchase Nutrition Depot Retail Stores II-51

US Farms Signs Agreement with EnergyAloe II-51

Dynova Laboratories Acquires SiCap Industries II-51

Interactive Digital Multimedia Purchases Go Healthy II-51

Guangdong Kangmei Pharmaceutical to Establish a New Subsidiary II-52

Plethico Pharmaceuticals to Sign Agreement with Molekule II-52

Hindustan Biosynth to Acquire Hindustan Pharmaceuticals II-52

Taisho Pharmaceutical to Enter Chinese Herbal Medicine Market II-52

China Dongsheng International Signs Letter of Intent II-52

Phytotech Extracts Enters into Joint Venture with European

Pharmaceutical Company II-53

Brunel Healthcare Acquires Galloway and Gerard House Brands II-53

9. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-54

Plethico Pharmaceuticals Acquires Natrol, Inc. II-54

CVC Acquires Personal Care Retail Chain II-54

Hain Celestial Acquires New Personal Care Product Brands II-54

Renhuang Pharmaceuticals Adds Herbal Extracting Facility II-54

OTPP Board and Ares Management Acquires GNC Parent Corp. II-54

Tetley Tea Obtains New Polish Tea Brands II-55

GeoPharma Gets Shareholders' Nod for Merger Proposal II-55

Himalaya Herbal Enters into Deal With Foreign Retail Chains II-55

Himalaya Starts Outlets II-55

Shauna Herbal to Open Branches in Dubai and Malaysia II-56

10. FOCUS ON SELECT GLOBAL PLAYERS II-57

Arizona Natural Products, Inc. (USA) II-57

Arkopharma SA (France) II-57

Bio-Botanica, Inc. (USA) II-57

Blackmores Ltd. (Australia) II-58

Emami Ltd (India) II-58

Emerson Ecologics, LLC. (USA) II-58

Himalaya Drug Company (India) II-58

Imperial Ginseng Products Ltd. (Canada) II-59

Indfrag Ltd. (India) II-59

International Vitamin Corp [IVC] (USA) II-60

Natrol, Inc. (USA) II-60

Nature's Answer (USA) II-60

Nature's Sunshine Products, Inc. (USA) II-61

NBTY, Inc. (USA) II-61

Sundown Nutrition (USA) II-61

Nutraceutical International Corporation (USA) II-62

Pharma Nord APS (Denmark) II-62

Pharmaton Natural Health Products (USA) II-63

Pharmavite® LLC (USA) II-63

Potters Herbal Medicines (UK) II-63

Ricola USA Inc (USA) II-63

DSM Nutritional Products Ltd. (Switzerland) II-64

Martek Biosciences Corporation (USA) II-64

i-Health, Inc (USA) II-64

TwinLab Corporation (USA) II-65

Nature's Herbs (USA) II-65

11. GLOBAL MARKET PERSPECTIVE II-66

Table 5: World Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin

America and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) II-66

Table 6: World Historic Review for Herbal Supplements and

Remedies by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America andRest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) II-67

Table 7: World 15-Year Perspective for Herbal Supplements and

Remedies by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) II-68

Table 8: World Recent Past, Current & Future Analysis for

Ginkgo Biloba by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-69

Table 9: World Historic Review for Ginkgo Biloba by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America & Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-70

Table 10: World 15-Year Perspective for Ginkgo Biloba by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-71

Table 11: World Recent Past, Current & Future Analysis for

Garlic by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-72

Table 12: World Historic Review for Garlic by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-73

Table 13: World 15-Year Perspective for Garlic by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan),Latin America

and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-74

Table 14: World Recent Past, Current & Future Analysis for

Ginseng by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-75

Table 15: World Historic Review for Ginseng by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-76

Table 16: World 15-Year Perspective for Ginseng by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-77

Table 17: World Recent Past, Current & Future Analysis for

Echinacea by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan),Latin America and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-78

Table 18: World Historic Review for Echinacea by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-79

Table 19: World 15-Year Perspective for Echinacea by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-80

Table 20: World Recent Past, Current & Future Analysis for St.

John's Wort by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-81

Table 21: World Historic Review for St. John's Wort by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-82

Table 22: World 15-Year Perspective for St. John's Wort by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-83

Table 23: World Recent Past, Current & Future Analysis for Soy

by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) II-84

Table 24: World Historic Review for Soy by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) II-85

Table 25: World 15-Year Perspective for Soy by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) II-86

Table 26: World Recent Past, Current & Future Analysis for

Aloe Vera by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-87

Table 27: World Historic Review for Aloe Vera by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-88

Table 28: World 15-Year Perspective for Aloe Vera by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-89

Table 29: World Recent Past, Current & Future Analysis for

Specialty Herbs by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-90

Table 30: World Historic Review for Specialty Herbs by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-91

Table 31: World 15-Year Perspective for Specialty Herbs by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-92

Table 32: World Recent Past, Current & Future Analysis for

Multi-Herbs by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-93

Table 33: World Historic Review for Multi-Herbs by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-94

Table 34: World 15-Year Perspective for Multi-Herbs by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-95

Table 35: World Recent Past, Current & Future Analysis for

Other Herbal Supplements by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) II-96

Table 36: World Historic Review for Other Herbal Supplements

by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-97

Table 37: World 15-Year Perspective for Other Herbal

Supplements by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets for

Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-98

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Wavering Herbal Supplements Market III-1

Dietary Supplements Market in the US III-1

Table 38: Supplements Market in the US (2008 & 2009):

Percentage Breakdown of Value Sales by Segment - Vitamins,

Herbs and Botanicals, Meal Supplements, Specialty/Others,

Minerals, and Sports Nutrition (includes corresponding

Graph/Chart) III-2

Herbal and Botanical Supplements Log Spike in Popularity III-2

Top 20 Most Popular Herbal Dietary Supplements in the US

(2009): Ranking Based on Value Sales in Food, Drug and Mass

Merchant Distribution Channel III-3

Alternative Medicine Finds Buyers Despite Slowdown in Economy III-4

Threat to Herbal Supplements and Remedies Market in the US III-4

Ray of Hope III-5

Herbal Supplements - Historic Review III-5

Expansion Beyond the 1960s III-5

Market in the 1990s III-6

Market Dynamics III-6

Consumer Trends III-6

Table 39: Herbal Medications in the US Market (2007 &

2008): Percentage Breakdown of Value Sales by

Disease/Condition - Cardiovascular, Respiratory,

Digestive, Tonics, Sedatives and Others(includes

corresponding Graph/Chart) III-7

Adult Usage of Health Supplements Increases III-7

Table 40: Vitamin and Herbal Supplements Market in the US

(2008): Percentage Breakdown by Frequency of Usage

(includes corresponding Graph/Chart) III-8

Table 41: US Market for Mineral Supplements: Breakdown of

Retail Dollar and Unit Sales of Top Brands for the Year

Ended October 2007 (includes corresponding Graph/Chart) III-8

Women' Healthcare Needs Propel Market III-9

Gamut of Soy Based Introductions III-9

Table 42: Ranking of Health Benefits offered by Soy in

Order of Consumer Awareness (2010) (includes corresponding

Graph/Chart) III-10

Major Distribution Outlets III-11

Table 43: Herbal Supplements Market in the US (2009 &

2010): Percentage Breakdown of Value Sales by Distribution

Channel - Mass Merchants, Natural & Health Food (NHF) and

Direct Sales (includes corresponding Graph/Chart) III-11

Market Competition in the Recent Past III-12

Table 44: Leading Brands in the US Herbal Supplements

Market (2005 & 2006): Percentage Breakdown of Value Sales

for Sundown Herbals, Nature's Resource, Healthy Woman,

Sundown, One-A-Day, Estroven, Sundown Herbals Extra,

Ginkoba, Nature Made and Others (includes corresponding

Graph/Chart) III-12

Legal & Regulatory Issues III-13

FDA Bans Ephedra Supplements III-13

FDA Orders Retraction of 'PC-Specs' III-13

'Ethyl Alcohol in Liquid Herbal Supplements Not Harmful' - FDA III-13

Labeling Regulations for Dietary Supplements III-13

Nutrition Labeling and Education Act III-14

Consumer Healthcare Products Association III-14

B.Market Analytics III-15

Table 45: US Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-15

Table 46: US Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-16

Table 47: US 15-Year Perspective for Herbal Supplements and

Remedies by Product Segment - Percentage Breakdown of Dollar

Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea, St.

John's Wort, Soy, Aloe Vera, Specialty Herbs, Multi-Herbs,

and Other Herbal Supplements Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) III-17

2. CANADA III-18

A.Market Analysis III-18

Market Overview III-18

Table 48: Canadian Natural Health Market (2008): Percentage

Breakdown of Sales of Natural Health Products-

Multi-vitamin, Herbal Supplements, Glucosamine, Calcium,

Vitamin C, Vitamin B, Vitamin E, Child Multi-Vitamins and

Antioxidant Supplements (includes corresponding

Graph/Chart) III-18

Demographic Trends Suggest Rising Preference III-19

Guidelines of Health Canada III-19

Ban on Kava Products III-19

B.Market Analytics III-20

Table 49: Canadian Recent Past, Current & Future Analysis

for Herbal Supplements and Remedies by Product Segment -

Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort,

Soy, Aloe Vera, Specialty Herbs, Multi-Herbs, and Other

Herbal Supplements Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) III-20

Table 50: Canadian Historic Review for Herbal Supplements

and Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-21

Table 51: Canadian 15-Year Perspective for Herbal

Supplements and Remedies by Product Segment - Percentage

Breakdown of Dollar Sales for Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets for Years 2003,2011 & 2017 (includes corresponding

Graph/Chart) III-22

3. JAPAN III-23

A.Market Analysis III-23

Market Overview III-23

Outlook III-23

Market Trends/Issues III-23

Emergence of Herbal Supplements III-24

Distribution Channels III-24

Favorable Demographics Drive Growth III-24

Imports of Herbal Products III-24

Laws Governing the Imports of Herbal Supplements Market III-24

Food Sanitation Law III-24

Plant Quarantine Law III-25

B.Market Analytics III-26

Table 52: Japanese Recent Past, Current & Future Analysis

for Herbal Supplements and Remedies by Product Segment -

Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort,

Soy, Aloe Vera, Specialty Herbs, Multi-Herbs, and Other

Herbal Supplements Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) III-26

Table 53: Japanese Historic Review for Herbal Supplements

and Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-27

Table 54: Japanese 15-Year Perspective for Herbal

Supplements and Remedies by Product Segment - Percentage

Breakdown of Dollar Sales for Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-28

4. EUROPE III-29

A.Market Analysis III-29

Overview III-29

Market Trends III-29

Inconsistent Market III-30

Regulatory Environment III-30

Marketing Opportunities for Natural Products III-30

Outlook III-31

European Herbal Market Perks Up III-32

Market Analysis III-32

Distribution Channels III-33

The Food Supplements Directive (FSD) Finalized III-33

ANH and EU Member States Dispute Food Supplements Directive III-34

B.Market Analytics III-35

Table 55: European Recent Past, Current & Future Analysis

for Herbal Supplements and Remedies by Geographic Region -

France, Germany, Italy, UK, Spain, Russia & Rest of Europe

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-35

Table 56: European Recent Past, Current & Future Analysis

for Herbal Supplements and Remedies by Product Segment -

Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort,

Soy, Aloe Vera, Specialty Herbs, Multi-Herbs, and Other

Herbal Supplements Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) III-36

Table 57: European Historic Review for Herbal Supplements

and Remedies by Geographic Region - France, Germany, Italy,

UK, Spain, Russia & Rest of Europe Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) III-37

Table 58: European Historic Review for Herbal Supplements

and Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-38

Table 59: European 15-Year Perspective for Herbal

Supplements and Remedies by Geographic Region - Percentage

Breakdown of Dollar Sales for France, Germany, Italy, UK,

Spain, Russia & Rest of Europe Markets for Years 2003, 2011

& 2017 (includes corresponding Graph/Chart) III-39

Table 60: European 15-Year Perspective for Herbal

Supplements and Remedies by Product Segment - Percentage

Breakdown of Dollar Sales for Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-40

4a. FRANCE III-41

A.Market Analysis III-41

Market Trends III-41

B.Market Analytics III-42

Table 61: French Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-42

Table 62: French Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-43

Table 63: French 15-Year Perspective for Herbal Supplements

and Remedies by Product Segment - Percentage Breakdown of

Dollar Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea,

St. John's Wort, Soy, Aloe Vera, Specialty Herbs,

Multi-Herbs, and Other Herbal Supplements Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-44

4b. GERMANY III-45

A.Market Analysis III-45

Contract Manufacturing on Rise III-45

Classification of Herbal Products III-45

Pharmacies: A Major Distribution Channel III-46

B.Market Analytics III-47

Table 64: German Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-47

Table 65: German Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-48

Table 66: German 15-Year Perspective for Herbal Supplements

and Remedies by Product Segment - Percentage Breakdown of

Dollar Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea,

St. John's Wort, Soy, Aloe Vera, Specialty Herbs,

Multi-Herbs, and Other Herbal Supplements Markets Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-49

4c. ITALY III-50

A.Market Analysis III-50

Italian Market for Nutritional Supplements Flourishes III-50

B.Market Analytics III-51

Table 67: Italian Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-51

Table 68: Italian Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-52

Table 69: Italian 15-Year Perspective for Herbal Supplements

and Remedies by Product Segment - Percentage Breakdown of

Dollar Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea,

St. John's Wort, Soy, Aloe Vera, Specialty Herbs,

Multi-Herbs, and Other Herbal Supplements Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-53

4d. THE UNITED KINGDOM III-54

A.Market Analysis III-54

Trends in Herbal Remedies Market III-54

Indian Herbal Remedies Had Bitter Experience in UK III-54

Key Distribution Channels III-54

B.Market Analytics III-55

Table 70: UK Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-55

Table 71: UK Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-56

Table 72: UK 15-Year Perspective for Herbal Supplements and

Remedies by Product Segment - Percentage Breakdown of Dollar

Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea, St.

John's Wort, Soy, Aloe Vera, Specialty Herbs, Multi-Herbs,

and Other Herbal Supplements Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) III-57

4e. SPAIN III-58

Market Analysis III-58

Table 73: Spanish Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-59

Table 74: Spanish Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-60

Table 75: Spanish 15-Year Perspective for Herbal Supplements

and Remedies by Product Segment - Percentage Breakdown of

Dollar Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea,

St. John's Wort, Soy, Aloe Vera, Specialty Herbs,

Multi-Herbs, and Other Herbal Supplements Markets Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-61

4f. RUSSIA III-62

Market Analytics III-62

Table 76: Russian Recent Past, Current & Future Analysis for

Herbal Supplements and Remedies by Product Segment - Ginkgo

Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy,

Aloe Vera, Specialty Herbs, Multi-Herbs, and Other Herbal

Supplements Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-62

Table 77: Russian Historic Review for Herbal Supplements and

Remedies by Product Segment - Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-63

Table 78: Russian 15-Year Perspective for Herbal Supplements

and Remedies by Product Segment - Percentage Breakdown of

Dollar Sales for Ginkgo Biloba, Garlic, Ginseng, Echinacea,

St. John's Wort, Soy, Aloe Vera, Specialty Herbs,

Multi-Herbs, and Other Herbal Supplements Markets for Years

2003, 2011 & 2017 (includes corresponding Graph/Chart) III-64

4g. REST OF EUROPE III-65

Market Analytics III-65

Table 79: Rest of Europe Recent Past, Current & Future

Analysis for Herbal Supplements and Remedies by Product

Segment - Ginkgo Biloba, Garlic, Ginseng, Echinacea, St.

John's Wort, Soy, Aloe Vera, Specialty Herbs, Multi-Herbs,

and Other Herbal Supplements Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-65

Table 80: Rest of Europe Historic Review for Herbal

Supplements and Remedies by Product Segment - Ginkgo Biloba,

Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-66

Table 81: Rest of Europe 15-Year Perspective for Herbal

Supplements and Remedies by Product Segment - Percentage

Breakdown of Dollar Sales for Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-67

5. ASIA-PACIFIC III-68

A.Market Analysis III-68

Focus on Select Markets III-68

Australia III-68

China III-68

Chinese Demand for Nutritional Supplements on the Rise III-68

Dietary Supplements and Vitamins Market on Growth Spree III-69

Amway: The Undisputed Market Leader III-69

Table 82: Leading Players in the Chinese Dietary

Supplements and Vitamins Market (2010): Percentage

Breakdown of Value Sales forAmway (China), Infinitus

(China), StoneGroup Holdings, Shandong Dong-E-E-

Jiao,Tianjin Tianshi Biological Development and Others III-69

Rapid Increase in Garlic Prices in China III-69

India III-70

Dietary Supplements and Nutraceutical Sales Grow Despite

Recession III-70

Huge Growth Potential for Indian Herbal Medicine Market III-70

Thailand III-71

Stiff Competition III-71

B.Market Analytics III-72

Table 83: Asia-Pacific Recent Past, Current & Future

Analysis for Herbal Supplements and Remedies by Geographic

Region - China, India, and Rest of Asia- Pacific Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-72

Table 84: Asia-Pacific Recent Past, Current & Future

Analysis for Herbal Supplements and Remedies by Product

Segment - Ginkgo Biloba, Garlic, Ginseng, Echinacea, St.

John's Wort, Soy, Aloe Vera, Specialty Herbs, Multi-Herbs,

and Other Herbal Supplements Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) III-73

Table 85: Asia-Pacific historic review for Herbal

Supplements and Remedies by Geographic Region - China,

India, and Rest of Asia-Pacific Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) III-74

Table 86: Asia-Pacific Historic Review for Herbal

Supplements and Remedies by Product Segment - Ginkgo Biloba,

Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) III-75

Table 87: Asia-Pacific 15-Year Perspective for Herbal

Supplements and Remedies by Geographic Region - Percentage

Breakdown of Dollar Sales for China, India, and Rest of

Asia-Pacific Markets forYears 2003, 2011 & 2017

(includescorresponding Graph/Chart) III-76

Table 88: Asia-Pacific 15-Year Perspective for Herbal

Supplements and Remedies by Product Segment - Percentage

Breakdown of Dollar Sales for Ginkgo Biloba, Garlic,

Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera,

Specialty Herbs, Multi-Herbs, and Other Herbal Supplements

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-77

6. LATIN AMERICA III-78

A.Market Analysis III-78

Mexico III-78

Garlic Consumption in Brazil Rises Despite Rising Prices III-78

B.Market Analytics III-79

Table 89: Latin American Recent Past, Current & Future

Analysis for Herbal Supplements and Remedies by Geographic

Region - Brazil and Rest of Latin America Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-79

Table 90: Latin American Recent Past, Current & Future

Analysis for Herbal Supplements and Remedies by Product

Segment - G

To order this report:

Vitamin and Supplement Industry: Global Herbal Supplements and Remedies Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

U.S. House of Representatives' Armed Services Committee And Appropriations Committee Provide Unprecedented Endorsement For The Development Of Reliable Diagnostic Tools For Prostate Cancer

Mon, 21 May 2012 12:15:00 +0000

U.S. House of Representatives' Armed Services Committee And Appropriations Committee Provide Unprecedented Endorsement For The Development Of Reliable Diagnostic Tools For Prostate Cancer

PR Newswire

Historic Victory in U.S. Congress is Scored as Legislation Includes Support for Research Funding to Advance Prostate Imaging Technologies

BOSTON, May 21, 2012 /PRNewswire-USNewswire/ -- Boston-based AdMeTech Foundation announces today an historic victory in the U.S. Congress for its public awareness and advocacy campaign "Where is Our Manogram?" Both the House Armed Services Committee and House Appropriations Committee showed support for this campaign through legislative language aimed at increasing the prioritization of prostate imaging research within the Department of Defense medical research programs.

The House Armed Services Committee Report accompanying the National Defense Authorization Act for fiscal year 2013 (H.R. 4310) recognized that "in spite of the magnitude of the prostate cancer epidemic in the military and civilian populations, men do not have reliable diagnostic tools for guiding early detection and treatment which is critical for saving lives, improving quality of life and reducing health care costs." The House approved H.R. 4310 on Friday by a 299-120 margin, sending the measure to the Senate. Echoing the historic decision by the Armed Services Committee, the House Appropriations Committee in its own Report accompanying the Fiscal Year 2013 DOD Appropriations bill, encouraged the Secretary of Defense "to fund research for the advancement of prostate imaging technologies" by the peer-review-based Prostate Cancer Research Program (within the Congressionally Directed Medical Research Program).

House Republicans and Democrats stood together to support improved prostate cancer diagnosis, and requested this legislative language on behalf of the AdMeTech Foundation-led campaign and its many stakeholders from around the nation. Among champions of either the Armed Services Committee or Appropriations Committee legislation were Rob Andrews (D-NJ), Todd Akin (R-MO), Chaka Fattah (D-PA), Walter Jones (R-NC), Dan Burton (R-IN), Elijah Cummings (D-MD), Steve Lynch (D-MA), Mike Capuano (D-MA), Niki Tsongas (D-MA), Ken Calvert (R-CA), Del. Donna Christensen (D-Virgin Islands), and Ed Towns (D-NY).

"AdMeTech is pleased to spearhead this effort, and is grateful to the many members of the U.S. House of Representatives, House Armed Services and Appropriations Committees for this unprecedented response," stated AdMeTech's President, Dr. Faina Shtern. "The prostate cancer crisis is a direct result of unreliable diagnostic tools. The extent of unnecessary and failed medical procedures is staggering. An American man dies every 16 minutes. With the increased national investment in research, improved diagnostic tools will become available to men within three to five years," she added.

Senators John Kerry and Scott Brown, State Senate President Therese Murray and Speaker of the House Robert DeLeo, as well as key legislators, and leaders of medicine and advocacy will address AdMeTech's Prostate Cancer Awareness Day at the Massachusetts State House on June 28. This annual event is creating a Massachusetts model of national leadership in recognizing the prostate cancer crisis and the need to improve diagnostic tools as a public health priority.

Prostate cancer – striking one in six men – is the most common major cancer in the United States. African American men have 60% higher incidence and 250% higher mortality. Prostate cancer has become more common than even breast cancer. However, public awareness and government investment in research are lagging behind, and men do not have accurate diagnostics akin to life-saving mammography. While curable when detected early, prostate cancer is the second most lethal cancer in men.

ABOUT AdMeTech Foundation:
AdMeTech is a nonprofit organization providing international leadership in the design and implementation of groundbreaking programs in research, education, awareness and advocacy dedicated to the advancement of diagnostic tools for early detection and treatment of prostate cancer. AdMeTech established the public awareness campaign "Where is Our Manogram?" in 2005. AdMeTech has been hosting an Annual Massachusetts State House Prostate Cancer Awareness Day, with recognition from the Governor, Massachusetts General Court and Boston City Council since 2009.

SOURCE AdMeTech Foundation

Hazards and Complications Associated With Gallbladder Surgery

Sun, 20 May 2012 07:11:52 +0000

Although routine, gallbladder surgery contains many unique risks and can have serious complications if not performed properly.

May 20, 2012 /24-7PressRelease/ -- The gallbladder is a little, non-essential organ attached to the liver that transports bile to the small intestine through the bile duct. Unfortunately, the organ can cause problems in those individuals that are susceptible to gallstones, or deposits that can be found in the gallbladder. Removal of the stones only results in more rapid production of more stones, so the only option for patients who suffer from gallstones is the removal of the gallbladder.

Although gallbladder surgery is relatively common, it can be rife with medical complications. Gallbladder surgical errors can result in severe infections that if not promptly detected and treated can even be fatal.

Gallstones Often Leave People With No Alternative to Surgery

Gallstones form when the liver is full of fatty substances as the result of diet or genetics. Sometimes, patients with gallstones do not experience any discomfort, but for some, the pain the stones cause to the upper abdomen can be serious. For these patients, the only option is surgery to remove the gallbladder, known as a cholecystectomy.

Two surgical options are available to patients who suffer from gallstones: laparoscopic cholecystectomy and a more traditional open surgery cholecystectomy. Laparoscopic surgery does not involve a large incision but small punctures that allow the laparoscope and other instruments to remove the gallstones. Normally, both are safe surgeries when elective, but medical risks increase when the gallstone removal surgery is an emergency.

Potential Dangers of Gallbladder Surgery

Several things can go wrong with both types of surgeries. Complications with laparoscopic surgery, such as punctures and perforations, usually compel surgeons to transition to a more conventional open surgery. A recent study found that some surgeons may not be experienced or have the right qualifications to perform laparoscopic cholecystectomies, which may lead to emergency open surgery cholecystectomies and contribute to medical errors.

The most serious medical complication during and following a cholecystectomy is the perforation of the bile duct, which can lead to infections, liver damage, and pancreatitis. In addition, surgery may not remove all the stones and can contribute to long-term stone recurrence if the gallbladder is not entirely removed.

Individuals with gallstone issues should carefully consider their surgical options before they commit to a procedure. If the gallstone surgery is an emergency, make sure to ask lots of questions before and after the procedure, if possible, so you can understand the risks of the operation.

There is a limited period of time for taking action in New York for medical negligence. If you been injured or a loved one has lost his/her life during or following gallstone surgery you should speak with an experienced New York City medical malpractice attorney. An attorney with a strong history of resolving medical malpractice cases can evaluate your claim.

Article provided by Law Offices Rosenberg, Minc, Falkoff & Wolff, L.L.P.

Visit us at www.medicalmalpractice.net

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com